

CURRICULUM VITAE

Mehdi H. Hamadani MD

Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:

1993 - 1994 Higher Secondary School Certificate (Pre-Medical), Government College, Lahore, Pakistan
1995 - 2001 M.B.B.S. (Honors), King Edward Medical College, Lahore, Pakistan

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

03/01/2003 - 07/30/2003 Research Officer, Hematology and Oncology, Shaukat Khanum Cancer Hospital and Research Center, Lahore, Pakistan
08/01/2003 - 07/31/2004 Intern, Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
08/01/2004 - 07/31/2006 Resident, Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
08/01/2006 - 07/31/2009 Fellow, Hematology and Oncology, The Ohio State University, Columbus, OH

FACULTY APPOINTMENTS:

08/01/2006 - 07/31/2009 Clinical Instructor of Medicine, Hematology and Oncology, The Ohio State University, Arthur G. James Comprehensive Cancer Center, Columbus, OH
08/04/2009 - 06/30/2013 Assistant Professor, Hematology and Oncology, Blood and Marrow Transplantation Program, West Virginia University-SOM, Morgantown, WV
08/04/2009 - 10/07/2013 Associate Member, Mary Babb Randolph Cancer Center, Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV
07/01/2013 - 10/07/2013 Associate Professor, Hematology and Oncology, Blood and Marrow Transplantation Program, West Virginia University-SOM, Morgantown, WV
10/14/2013 - 06/30/2018 Associate Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
07/01/2018 - Present Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

2009 - 2013 Attending Physician, Hematological Malignancy Service, Ruby Memorial Hospital, WVU
2009 - 2013 Attending Physician, Bone Marrow Transplantation Unit, Ruby Memorial Hospital, WVU
2009 - 2013 Attending Physician, Hematological Malignancy Clinic, Mary Babb Randolph Cancer Center, WVU, Morgantown, WV
04/11/2012 - 10/07/2013 Medical Director, Myeloma and Lymphoma, Hematology and Oncology, West Virginia University, Mary Babb Randolph Cancer Center, Morgantown, WV
10/14/2013 - Present Scientific Director, CIBMTR-Center for International Blood and Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI
2013 - Present Attending Physician, Hematological Malignancy Clinic, Froedtert Clinical Cancer Center, MCW, Milwaukee, WI
2013 - Present Attending Physician, Bone Marrow Transplantation Unit, Froedtert Memorial Lutheran

Hospital, MCW, Milwaukee, WI
 2013 - Present Attending Physician, Hematological Malignancy Service, Froedtert Memorial Lutheran Hospital, MCW, Milwaukee, WI
 11/01/2017 - Present Director, Adult BMT & Cellular Therapy Program, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 12/01/2017 - Present Chair, BMT & Cellular Therapy Program, Disease Oriented Team, Medical College of Wisconsin, Milwaukee, WI
 09/01/2023 - Present Chief, Section of Hematologic Malignancies, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:

2009 - 2013 Attending Physician, Mary Babb Randolph Cancer Center, Hematological Malignancy Clinic, West Virginia University, WV
 2009 - 2013 Attending Physician, Ruby Memorial Hospital, Hematological Malignancy Service, West Virginia University, WV
 2009 - 2013 Attending Physician, Ruby Memorial Hospital, Bone Marrow Transplantation Unit, West Virginia University, WV
 2013 - Present Attending Physician, Clinical Cancer Center, Hematological Malignancy Clinic, Froedtert & Medical College of Wisconsin, WI
 2013 - Present Attending Physician, Froedtert Memorial Lutheran Hospital, Hematological Malignancy Service, Froedtert & Medical College of Wisconsin, WI
 2013 - Present Attending Physician, Froedtert Memorial Lutheran Hospital, Bone Marrow Transplantation Unit, Froedtert & Medical College of Wisconsin, WI

SPECIALTY BOARDS AND CERTIFICATION:

<u>Certificates</u>	<u>Issued By</u>	<u>Issue Date</u>	<u>Expiration</u>
ECFMG	Step 1: 99/255; Step 2: 97/258; Step 3: 89/217; CSA: Passed	2002	2003
Internal Medicine	ABIM	2006	2016
Medical Oncology	ABIM	2009	2019
Hematology	ABIM	2010	2030

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Oklahoma Board of Medical Licensure and Supervision	23561	2003	2006
State Medical Board of Ohio	57-011465	2006	2009
West Virginia Board of Medicine	23463	2009	2014
WI license	61253-20	2012	2025

AWARDS AND HONORS:

1995 Merit Scholarship, Pakistan Atomic Energy Foundation
 1995 Merit Scholarship, Board of Intermediate and Secondary Education
 1997 Gold Medal for Under Graduate Research, Pakistan Physiological Society, King Edward Medical College
 2001 Lt. General Burki Gold Medal in Clinical Ophthalmology, King Edward Medical College
 09/2004 1st Place, Original Research Competition, American College of Physicians, Oklahoma Chapter Scientific Session
 09/2004 1st Place in American College of Physicians Original Research Competition, Oklahoma Chapter Scientific Session
 08/2007 Selected participant, ASCO/AACR Workshop: Methods in Clinical Cancer Research
 02/2009 Travel Grant, American Society for Bone Marrow Transplantation

06/2009 Excellence in Hematology & Oncology Research Award, The Ohio State University
06/2009 James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, The Ohio State University
06/2009 Clinical Research Impact Recognition by Faculty, 1000 Medicine
2009 Young Investigator Award, KEMCAANA
02/2011 New Investigator Award, ASBMT & Millennium
05/2011 Press Ganey Top Doctors Award, WVU Healthcare
05/2011 Press Ganey Top Doctors Award, WVUH Healthcare, Morgantown, WVU Healthcare
06/2011 Career Development Award, Conquer Cancer Foundation of ASCO
06/2011 Best Attending Physician, WVU Department of Internal Medicine
06/2012 Selected for inclusion in Academic Keys Who's Who in Medicine Academia
05/2013 Press Ganey Top Provider for Inpatient Service WVU Hospitals, Morgantown, WVU Hospitals
05/2013 Press Ganey Top Provider for Outpatient Clinics, WVU Hospitals
06/2013 Outstanding Teacher Award, WVU Department of Internal Medicine
2015 - 2016 Best Doctors in America
2016 - 2017 Best Doctors in America
2017 - 2018 Best Doctors in America
09/2018 MCW Cancer Center Outstanding Achievement Award for Adult Clinical Research
10/2018 Magnanimous Mentor , Medical College of Wisconsin
2019 - 2020 Best Doctors in America
02/2020 BMT CTN Purple Heart Award
2020 - 2021 Best Doctors in America®
2020 Castle Connolly Top Doctor
2021 Castle Connolly Top Doctor

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

2001 - Present Pakistan Medical and Dental Council
2003 - 2004 American College of Physicians
2006 - 2008 American Medical Association
2007 - 2008 American Association for Cancer Research
2007 - Present American Society of Clinical Oncology
2007 - Present American Society of Hematology
2007 - Present American Society for Blood and Marrow Transplantation
2009 - Present Eastern Cooperative Oncology Group
2009 - Present West Virginia Oncology Society
2010 - Present West Virginia State Medical Association
2012 - Present Alliance for Clinical Trials in Oncology

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorship

2010 52nd American Society of Hematology Annual Meeting
2014 - Present Leukemia
2016 58th American Society of Hematology Annual Meeting
2017 59th American Society of Hematology Annual Meeting
2017 - 2019 ASH News Daily
2017 - Present HCT for Malignant Conditions
2017 - Present Hematopoietic Cell Transplant for Malignant Conditions
2019 - Present 61st American Society of Hematology Annual Meeting
2019 - Present American Society of Clinical Oncology Annual Meeting
2020 62nd American Society of Hematology Annual Meeting
2020 - Present Hematology Oncology & Stem Cell T
2020 - Present American Society of Clinical Oncology Annual Meeting
2021 - Present American Society of Clinical Oncology Annual Meeting

Editorial Board

2010 - 2013 Journal of Blood Disorders and Transfusion
2011 - Present World Journal of Transplantation
2011 - Present American Journal of Blood Research

2012 - Present Modern Chemotherapy
2014 - Present Bone Marrow Transplantation
2016 - Present Clinics in Oncology
2017 - Present Advances in Cell & Gene Therapy
2018 - Present Clinical Lymphoma, Myeloma & Leukemia
2019 - Present PLOS One

Ad-Hoc Reviewer

2005 - Present American Journal of Health System Pharmacy
2006 - Present Journal of Postgraduate Medicine
2007 - Present Indian Journal of Cancer
2007 - Present Journal of Medical Case Reports
2007 - Present Biology of Blood and Marrow Transplantation
2007 - Present Southern Medical Journal
2007 - Present Medical Science Monitor
2008 - Present Bone Marrow Trnasplantation
2009 - Present Expert Review of Anticancer Therapy
2009 - Present Haematologica
2009 - Present Leukemia and Lymphoma
2010 - Present Drugs
2010 - Present Advances in Hematology
2010 - Present US Hematology
2011 - Present Journal of Oncology
2011 - Present American Journal of Hematology
2012 - Present Experimental Hematology & Oncology
2012 - Present Hematology Reports
2013 - Present British Journal of Haematology
2013 - Present Blood
2013 - Present Cytotherapy
2013 - Present JSM Hematology & Transfusion
2013 - Present Clinical Transplantation
2015 - Present Journal of Clinical Apheresis
2015 - Present Clinical Lymphoma, Myeloma & Leukemia
2015 - Present Journal of Clinical Oncology
2016 - Present Journal of Community and Supportive Oncology
2016 - Present Oncoimmunology
2016 - Present Hematology/Oncology and Stem Cell Therapy
2017 - Present Blood Advances
2018 - Present Lancet Haematology
2018 - Present Cancer
2018 - Present Annals of Hematology
2018 - Present Lancet Oncology
2019 - Present ASH Hematology, The Education Program

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2009 - 2013 Member, Protocol Review and Monitoring Committee, WVU
2009 - 2013 Chair, Data Safety and Toxicity Committee, MBRCC
2009 - 2013 Member, IM Residency Candidate Interview Committee, WVU
2010 - 2013 Member, Fellowship Education Sub-Committee, WVU
2011 - 2013 Member, Fellowship Recruitment Committee, WVU
2011 - 2012 Member, Hematology/BMT Faculty Search Committee, WVU
2012 - 2013 Member, Elections Committee, West Virginia Oncology Society
2012 - 2013 Member, Research Committee, WVU
2013 - 2015 Member, Young Investigator Award Committee, KEMCAANA
2013 - 2014 Member, Antimicrobial Stewardship Advisory Group, MCW
2015 - 2020 Member, PNT Oncology Subcommittee, MCW
2016 - 2019 Member, Data Safety and Monitoring Committee, MCW
2016 - 2021 Member, Fellowship Recruitment Committee, MCW

2017 - 2019 Chair, Accountable Care Team-BMT Service Line/8-CFAC, MCW
 2017 - Present Chair, BMT Faculty Research Committee, MCW
 2017 - 2021 Member, Clinical Program Leadership, F&MCW
 2019 - 2020 Member, Chicago Lymphoma Symposium Advisory Committee

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2009 - 2016 Member, Multiple Myeloma Working Committee, CIBMTR
 2009 - 2013 Member, Hodgkin and NHL Working Committee, CIBMTR
 2009 - 2013 Member, Chronic Leukemia Working Committee, CIBMTR
 2009 - 2013 Member, Acute Leukemia Working Committee, CIBMTR
 2012 - 2013 Principal Investigator, Alliance for Clinical Trials in Oncology, WVU
 2013 - Present Scientific Director, Lymphoma Working Committee, CIBMTR
 2013 - 2019 Protocol Officer, 1501 Study Protocol Team, BMT CTN
 2013 - 2014 Member, Steering Committee, BMT CTN
 2013 - 2018 Member, CLT-008 Data Safety & Monitoring Board, Cellera
 2014 - 2022 Protocol Officer, 1506 Study Protocol Team, BMT CTN
 2015 - 2017 Member, Friday Satellite Symposia Study Section, ASH
 2016 - 2022 Member, Practice Guidelines Committee, ASBMT
 2016 - 2022 Member, 1503 Eligibility Review Committee, BMT CTN
 2017 - 2018 Chair, Friday Satellite Symposia Study Section, ASH
 2017 - 2018 Member, Industry Engagement Task Force, BMT CTN
 2018 Member, Working Group on Media Strategy, ASH
 2018 - 2020 Protocol Officer, 1802 Study Protocol Team, BMT CTN
 2018 - 2022 Protocol Officer, 1703 Study Protocol Team, BMT CTN
 2018 - Present Protocol Officer, 1705 Study Protocol Team, BMT CTN
 2018 - 2019 Member, Program Committee, ASH
 2019 - Present Protocol Officer, 1904 Study Protocol Team, BMT CTN
 2019 - 2020 Track Leader - Leukemia/Transplant), ASCO Annual Meeting Education Committee
 2019 - Present Member, Scientific Program Committee, ASCO
 2020 - 2021 Course Director, 1st Midwest Cellular Conference
 2020 - Present Co-Chair, Practice Guidelines, ASTCT
 2020 - 2021 DCC Liaison, SOSS Lymphoma Committee, BMT CTN
 2020 - 2022 Protocol Officer, 2002 Study Protocol Team, BMT CTN

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title: U24 HL138660 Blood and Marrow Transplantation Clinical Research Network Data Coordinating Center.
 Source: NHLBI
 Role & Effort: Co-Investigator
 PI: Mary Horowitz
 Dates: 09/15/2017 - 08/31/2024
 Direct Funds: \$45,673,177 (0.6 Cal (Yr 2-3) 2.4 Cal (Yr 4-7))

Title: BMT-CTN 1506: A multicenter, randomized, double-blind placebo-controlled phase III trial of the FLT3 inhibitor gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3-ITD AML.
 Source: NHLBI
 Role & Effort: Protocol Officer

Dates: 10/01/2017 - 09/30/2025

Title: A phase II, open-label, study of propylene glycol-free melphalan HCl in combination with fludarabine and total body irradiation based reduced intensity conditioning for haploidentical transplantation.

Source: Spectrum Pharmaceuticals
Role & Effort: Principal Investigator
Dates: 03/13/2018 - 12/31/2026
Direct Funds: \$108,685

Title: A multicenter, open label phase 1/2 study of Cyt-0851, an oral Rad51 inhibitor, in patients with relapsed/refractory B-cell malignancies and advanced solid tumors.

Source: Cyteir
Role & Effort: Institutional PI
Dates: 2020 - Present

Title: INCB-50465-204: A phase 2, open-label, 2-cohort study of INCB050465, a PI3K Inhibitor, in subjects with relapsed or refractory marginal zone lymphoma with or without prior exposure to a BTK inhibitor (CITADEL-204).

Source: Incyte
Role & Effort: Institutional PI

Title: A phase 2, open-label, single-arm study to evaluate the efficacy and safety of camidanlumab tesirine (ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma.

Source: ADC Therapeutics
Role & Effort: Institutional PI

Title: INCB-50465-204: A phase 2, open-label, 2-cohort study of INCB050465, a PI3K Inhibitor, in subjects with relapsed or refractory marginal zone lymphoma with or without prior exposure to a BTK inhibitor (CITADEL-204).

Source: Incyte
Role & Effort: Institutional PI

Title: PrE0404: A phase I/II study of ixazomib and ibrutinib in relapsed/refractory mantle cell lymphoma.

Source: PrECOG
Role & Effort: Study Chair

Title: BMT-CTN 1703: A randomized, multicenter, phase III trial of tacrolimus/methotrexate vs post-

transplant cyclophosphamide/
tacrolimus/mycophenolate mofetil in
mon-myeloablative/reduced intensity
conditioning allogeneic peripheral blood
transplantation.

Source: NHLBI
Role & Effort: Protocol Officer

Title: CYTEIR-CYT-0851-01-REFMAL639:
A multicenter, open label phase 1/2
study of Cyt-0851, an oral Rad51
inhibitor, in patients with
relapsed/refractory B-cell malignancies
and advanced solid tumors.

Source: Cyteir
Role & Effort: Institutional PI

Title: IIT Hamadani FLU-MEL-TBI: A phase
II, open-label, study of propylene glycol-
free melphalan HCl (EVOMELA®) in
combination with fludarabine and total
body irradiation based reduced intensity
conditioning for haploidentical
transplantation.

Source: Spectrum
Role & Effort: Principal Investigator

Title: WVU-11310: Once daily intravenous
Busulfex as part of reduced toxicity
conditioning for patients with
relapsed/refractory Hodgkin and non-
Hodgkin lymphomas undergoing
allogeneic hematopoietic cell
transplantation - A multicenter phase II
study.

Source: OPDC Inc.
Role & Effort: Principal Investigator

Prior

Peer Review

Title: A multi-center phase II trial of once
daily intravenous Busulfex® as part of
reduced intensity conditioning for
patients with relapsed/refractory
Hodgkin and non-Hodgkin lymphomas.

Source: Otsuka Pharmaceutical Development &
Commercialization, Inc.

Role & Effort: Principal Investigator

Dates: 03/01/2010 - 12/31/2013

Direct Funds: \$143,058

Title: Atorvastatin for the prophylaxis of acute
graft-versus-host-disease in patients
undergoing allogeneic stem cell
transplantation

Source: American Cancer Society

116837-IRG-09-061-01	
Role & Effort:	Principal Investigator
Dates:	04/13/2010 - 12/31/2011
Direct Funds:	\$30,000 (Per Year)
Title:	Morphologic, immunophenotypic and molecular subtyping of high-grade large B-cell lymphomas: A clinicopathologic evaluation targeting myc, bcl2, bcl6 status and gene expression profiling as potential diagnostic and prognostic markers in large B-cell lymphomas with aggressive features
Source:	WVU MBRCC Pilot Project Grant
Role & Effort:	Co-Investigator
PI:	Jeffrey A. Vos, MD
Dates:	04/13/2010 - 12/31/2011
Direct Funds:	\$30,000 (Per Year)
Title:	Relative importance of intravenous Busulfex's dose-intensity in two Flu/Bu/ATG based reduced intensity conditioning regimens
Source:	Otsuka Pharmaceutical Development & Commercialization, Inc.
Role & Effort:	Principal Investigator
Dates:	08/02/2010 - 12/31/2011
Direct Funds:	\$14,192
Title:	Atorvastatin for the prophylaxis of acute graft-versus-host-disease in patients undergoing matched sibling allogeneic transplantation.
Source:	Conquer Cancer Foundation of ASCO Career Development Award
Role & Effort:	Principal Investigator
Dates:	07/01/2011 - 06/30/2014
Direct Funds:	\$66,666 (Per Year)
Title:	Atorvastatin for the prophylaxis of acute graft-versus-host-disease in patients undergoing matched sibling allogeneic transplantation
Source:	ASBMT & Millennium New Investigator Award
Role & Effort:	Principal Investigator
Dates:	07/01/2011 - 06/30/2013
Direct Funds:	\$30,000 (Per Year)
Title:	Assessment of micro-RNA 155 expression in acute graft-versus-host disease
Source:	WVCTSI & Ohio State CCTS Collaboration Pilot Award
Role & Effort:	Principal Investigator
Dates:	05/01/2012 - 04/30/2013
Direct Funds:	\$50,000 (Per Year)

Title: MLN9708 for the prophylaxis of chronic graft-versus-host disease in patient undergoing allogeneic transplantation.
Source: Millennium: The Takeda Oncology Company
Role & Effort: Principal Investigator
Dates: 01/10/2014 - 01/29/2017

Title: CP-204: An open-label, phase 1/2 study of MEDI-551, a humanized monoclonal antibody directed against CD19, in relapsed or refractory advanced B-cell malignancies
Source: Medimmune, LLC
Role & Effort: Institutional PI
Dates: 07/17/2014 - 02/11/2020
Direct Funds: \$145,596

Title: A multi-center, randomized, double-blind, placebo-controlled phase III trial of the FLT3 inhibitor gilteritinib.
Source: Astellas Pharma US Inc.
Role & Effort: Principal Investigator
Dates: 03/01/2015 - 01/29/2017
Direct Funds: \$1,532,581

Title: ADCT-301-001: ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma
Source: ADCT Therapeutics
Role & Effort: Institutional PI
Dates: 06/2015 - 06/2019
Direct Funds: \$315,721

Title: SGN19A-003: Randomized open-label phase 2 SGN-CD19A plus RICE vs. RICE for relapsed or refractory diffuse DLBCL.
Role & Effort: Institutional PI
Dates: 10/2015 - 06/2017

Title: Merck-MK-3475-170: A phase II study of pembrolizumab in subjects with relapsed or refractory primary mediastinal large B-cell lymphoma or relapsed or refractory Richter Syndrome.
Source: Merck Sharp & Dohme Corp.
Role & Effort: Institutional PI
Dates: 11/2015 - 02/2018

Title: Merck-MK-3475-013: A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies
Source: Merck Sharp & Dohme Corp.
Role & Effort: Institutional PI

Dates:	01/12/2016 - 10/24/2019
Direct Funds:	\$222,649
Title:	ADCT-402-101: A Phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma.
Source:	Pharmaceutical Research Associates, Inc.
Role & Effort:	Institutional PI
Dates:	06/07/2016 - 04/29/2020
Direct Funds:	\$673,676
Title:	SGN19A-003: A randomized, open-label phase 2 study of SGN-CD19A plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs RICE in the treatment of patients with relapsed or refractory diffuse large B-Cell lymphoma who are candidates for autologous stem cell transplant.
Source:	Seattle Genetics, Inc.
Role & Effort:	Institutional PI
Dates:	06/14/2016 - 08/01/2018
Direct Funds:	\$68,664
Title:	BMT-CTN 1501: A randomized phase II multi-center open label study comparing sirolimus to prednisone in patients with refined Minnesota standard risk, Ann Arbor 1/2 Confirmed acute GVHD.
Source:	NCI/NIH
Role & Effort:	Protocol Officer/Institutional PI
Dates:	09/2016 - 09/2019
Title:	MedImmune D4190C00023: A phase 1b study to evaluate the safety and efficacy of MEDI4736 as monotherapy and in combination with tremelimumab or AZD9150 in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Source:	MedImmune LLC
Role & Effort:	Institutional PI
Dates:	12/27/2016 - 03/15/2019
Direct Funds:	\$27,416
Title:	A prospective, multicenter observational study to evaluate hematopoietic progenitor cell mobilization in patients with newly diagnosed multiple myeloma.
Source:	Sanofi Genzyme
Role & Effort:	Principal Investigator
Dates:	05/22/2017 - 05/22/2022

Direct Funds:	\$2,059,830 (Effort: 11%)
Title:	SC17-03 - A multi-center, prospective, observational long-term study of the use of TEPADINA in Canadian and America Patients.
Source:	ADIENNE SA
Role & Effort:	Principal Investigator
Dates:	07/10/2017 - 07/09/2019
Direct Funds:	\$1,896,295
Title:	INCB-50465-102: An open-label, dose-finding, and cohort-expansion phase 1 study evaluating safety and efficacy of the study drug in combination with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma.
Source:	Incyte Corporation
Role & Effort:	Institutional PI
Dates:	11/10/2017 - 05/20/2019
Direct Funds:	\$96,592
Title:	A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Source:	Incyte Corporation
Role & Effort:	Site PI
Dates:	11/29/2017 - 11/28/2020
Title:	HOFFMANN-LAROCHE-GO40515: A phase Ib/II, open-label, multicenter, randomized, controlled study investigating the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab (BTCT4465A) in combination with CHOP or CHP-polatuzumab vedotin in patients with B-Cell non-Hodgkin Lymphoma.
Source:	Genentech
Role & Effort:	Institutional PI
Dates:	03/06/2019 - 08/27/2019
Title:	BMT-CTN 1802: An open-label, single-arm, multicenter study, of combination anti-CD3/CD7 immunotoxin (T-Guard) for steroid-refractory acute graft-versus-host disease.
Source:	NHLBI
Role & Effort:	Protocol Officer
Dates:	2020 - Present
Title:	E2408: A 3-arm randomized phase II trial of bendamustine-rituximab (BR) followed by rituximab vs. bortezomib-

Source: Role & Effort:	BR (BVR) followed by rituximab vs. BR Followed by lenalidomide/rituximab in high risk follicular lymphoma ECOG Institutional PI
Title:	Phase 1/2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01-T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma
Source: Role & Effort:	Senesco Institutional PI
Title:	CALGB 50303: Phase III randomized study of R-CHOP v. dose-adjusted EPOCH-R with molecular profiling in untreated de novo diffuse large B-cell lymphomas
Source: Role & Effort:	CALGB Institutional PI
Title:	BMT-CTN 0702: A trial of single autologous transplant with or without consolidation therapy versus tandem autologous transplant with lenalidomide maintenance for patients with multiple myeloma
Source: Role & Effort:	NHLBI Institutional PI
Title:	CP204-II: An open-label, phase 1/2 study of MEDI-551, a humanized monoclonal antibody directed against CD19, in adult subjects with relapsed or refractory advanced B-cell malignancies
Source: Role & Effort:	MedImmune Institutional PI
Title:	C25003: A randomized, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma
Source: Role & Effort:	Millennium Institutional PI
Title:	Merck-MK-3475-013: A phase Ib multi- cohort trial of MK-3475 (pembrolizumab) in subjects with hematologic malignancies
Source: Role & Effort:	Merck Institutional PI
Title:	ECOG 1411: Intergroup randomized, four arm phase II study in patients ≥60 with previously untreated MCL

Source: ECOG
Role & Effort: Institutional PI

Title: C16006: An open-label, dose-escalation, phase 1/2 study of the oral form of MLN9708, a second-generation proteasome inhibitor, administered in combination with lenalidomide and low-dose dexamethasone in patients with newly diagnosed multiple myeloma requiring systemic treatment

Source: Millennium
Role & Effort: Institutional PI

Title: MEDI-551-1088: A phase 2 randomized open-label study of MEDI-551 in adults with relapsed or refractory DLBCL

Source: MedImmune
Role & Effort: Institutional PI

Title: Gilead 218-1502: Phase 2b randomized, double-blind, placebo-controlled multicenter study GS-5806 in HCT recipients with RSV lower respiratory tract.

Source: Gilead
Role & Effort: Institutional PI

Title: A phase II study of oral single agent panobinostat in patients with refractory de-novo or secondary acute myelogenous leukemia

Source: Novartis Corp
Role & Effort: Institutional PI

Title: PCI- 32765CLL3001: Randomized, double-blind, placebo-controlled phase 3 Study of Ibrutinib, in Combination with bendamustine and rituximab in subjects with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Source: Janssen R&D
Role & Effort: Institutional PI

Title: Gilead 218-0108: Phase 2b randomized, double-blind, placebo-controlled multicenter study GS-5806 in HCT recipients with RSV upper respiratory tract

Source: Gilead
Role & Effort: Institutional PI

Title: MEDI-551-1088: A phase 2 randomized open-label study of MEDI-551 in adults with relapsed or refractory DLBCL

Source: MedImmune
Role & Effort: Institutional PI

Title: A randomized phase II trial of R-Hyper-CVAD induction followed by consolidation with an autologous transplant versus R-bendamustine induction followed by an autologous transplant for patients ≥65 years with previously untreated mantle cell lymphoma

Source: SWOG

Role & Effort: Institutional PI

Title: A phase II trial of PET-directed therapy for limited stage diffuse large B-cell lymphoma

Source: SWOG

Role & Effort: Institutional PI

Title: PANORAMA 1: A multicenter, randomized double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma

Source: Novartis Corp

Role & Effort: Institutional PI

Title: C16005: An open label, dose escalation, phase I/II study of the oral form of MLN9708, a second generation proteasome inhibitor administered in combination with lenalidomide and low dose dexamethasone in patients with newly diagnosed multiple myeloma requiring systemic treatment

Source: Millennium

Role & Effort: Institutional PI

Title: Phase II study to evaluate the efficacy and safety of ibrutinib in subjects with mantle cell lymphoma who progress after bortezomib therapy

Source: Janssen R&D

Role & Effort: Institutional PI

Title: Complement A/B: A randomized, open label study of ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B-cell non-Hodgkin's lymphoma unresponsive to rituximab or a rituximab-containing regimen during or within six months of treatment

Source: GlaxoSmithKline

Role & Effort: Institutional PI

Title: BMT-CTN 0701: Phase II trial of non-

myeloablative allogeneic hematopoietic cell transplantation for patients with relapsed follicular non-Hodgkin's lymphoma beyond first complete response

Source: NHLBI
Role & Effort: Institutional PI

Title: ADCT-402-201-DLBCL: A phase 2 open-label single-arm study to evaluate the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

Source: ADCT Therapeutics
Role & Effort: Institutional PI

Title: NU 14H09: A phase I-II trial of DA-EPOCH-R plus ixazomib as frontline therapy for patients with MYC-aberrant lymphoid malignancies: The DACIPHOR regimen.

Source: Takeda
Role & Effort: Institutional PI

Title: UNUM-ATTCK-20-03-BCL: Phase 1 study of ACTR707, an autologous T cell product, in combination with rituximab, in subjects with relapsed or refractory CD20+ B cell lymphoma.

Source: Unum Therapeutics
Role & Effort: Institutional PI

Title: IISR X16034: MLN9708 for the prophylaxis of chronic graft-versus-host disease in patient undergoing allogeneic transplantation. A phase I/II study.

Role & Effort: Principal Investigator

Title: A phase II study of ATRA, arsenic trioxide and gemtuzumab ozogamicin in patients with previously untreated high-risk acute promyelocytic leukemia

Source: SWOG
Role & Effort: Institutional PI

Title: PLEX-09: A phase II study evaluating the safety and efficacy of subcutaneous plerixafor for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in recipients with hematological malignancies

Source: RCI-BMT
Role & Effort: Institutional PI

Title: MEDI-551-1019: A phase 2 open-label study of MEDI-551-1019 and

Source: bendamustine vs. rituximab and
Role & Effort: bendamustine in adults with relapsed or
refractory CL
MedImmune
Institutional PI

Title: ARD12130: A Phase 2 study of
SAR245409 in patients with relapsed or
refractory mantle cell lymphoma,
follicular lymphoma, or chronic
lymphocytic leukemia/small
lymphocytic lymphoma

Source: Sanofi Aventis
Role & Effort: Institutional PI

Title: A phase I/II study of the tolerability of
lenalidomide and low dose
dexamethasone in previously treated
multiple myeloma patients with impaired
renal function

Source: PrEOCG
Role & Effort: Institutional PI

Title: MEDI D2852C00004: A Phase 1b/2
open-label study to evaluate the
safety/efficacy of MEDI-551 in
combination with immunomodulating
therapy in subjects with relapsed or
refractory aggressive B-cell lymphomas

Source: MedImmune
Role & Effort: Institutional PI

Title: C16012: A phase 3, randomized, two-
arm, open label, multicenter,
international trial of alisertib or
investigator choice in patients with
relapsed or refractory peripheral T-cell
lymphoma

Source: Millennium
Role & Effort: Institutional PI

Title: A randomized, open-label, multi-Center,
phase 2 study of zevalin(I90Y-
ibritumumab tiuxetan) versus zevalin
and motexafin gadolinium in patients
with rituxan-refractory low-grade or
follicular B-cell non-Hodgkin lymphoma

Source: SPI
Role & Effort: Institutional PI

Title: CLBH589E2301: A phase III
randomized double blind, placebo
controlled multi-center study of
panobinostat for maintenance of
response in patients with Hodgkin's
lymphoma who are at risk for relapse
after high dose chemotherapy and

Source:	autologous stem cell transplant
Role & Effort:	Novartis Corp Institutional PI
Title:	Assessment of micro-RNA 155 expression in acute graft-versus-host disease.
Source:	WVUCTSI/OSU-CCTS
Role & Effort:	Co-Principal Investigator
Title:	MCW & WVU-011012: Phase II study of atorvastatin, micro-dose methotrexate and tacrolimus administered only to transplant recipients for the prophylaxis of acute graft-versus-host disease following matched sibling and unrelated donor allogeneic hematopoietic cell transplantation.
Source:	CCF of ASCO
Role & Effort:	Principal Investigator
Title:	JUNO-JCAR017-017006: A phase 2 study of lisocabragene maraleucel (JCAR017) as second-line therapy in adult patients with aggressive B-cell NHL.
Source:	Celgene Corporation
Role & Effort:	Institutional PI
Title:	Phase II study evaluating the safety and efficacy of atorvastatin for the prophylaxis of acute graft-versus-host disease in patients undergoing matched sibling hematopoietic stem cell transplantation.
Source:	ASC-IRG; ASCO, ASMBT
Role & Effort:	Principal Investigator

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

Diffuse large B-cell lymphoma, APPNA MERIT (Medical Education & Research International Training & Transfer of Technology) Initiative Webinar, Karachi & Lahore, Pakistan, 06/10/2011

Lymphoma and plasma cell disorders: Invited faculty for poster discussion session, American Society of Clinical Oncology Annual Meetings, Chicago, IL, 06/03/2013

Clinical allogeneic and autologous transplantation - results: allogeneic transplantation, American Society of Hematology Annual Meetings, New Orleans, LA, 12/10/2013

Moving the needle: Potential effects of novel drug combinations on care in lymphoma, American Society of Clinical Oncology Annual Meetings, Chicago, IL, 05/31/2015

Clinical autologous transplantation - results: clinical autologous transplantation in myeloma I., American Society of Hematology, San Diego, CA, 12/05/2016

Establishing a curriculum for training in HCT: Roundtable discussion., WBMT, Riyadh, Saudi Arabia, 01/16/2017

Transplantation for DLBCL and follicular lymphoma., WBMT, Riyadh, Saudi Arabia, 01/17/2017

Are haploidentical transplants ready for prime time in lymphomas?, 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France, 03/29/2017

Clinical autologous transplantation: Modern indications and post-transplantation check point inhibitors in

lymphomas and myeloma., American Society of Hematology Annual Meeting, Atlanta, GA, 12/10/2017

Palliative/supportive care and histocompatibility., ASBMT & CIBMTR BMT Tandem Meetings., Salt Lake City, UT, 02/22/2018

Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma., American Society of Hematology Annual Meeting, San Diego, CA, 12/03/2018

Allogeneic hematopoietic cell transplantation in elderly (>65 years) non-Hodgkin lymphoma patients: A time trends analysis from the CIBMTR., 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, Frankfurt, Germany, 03/26/2019

? Meet the Professors: When do I consider stem cell transplant in relapsed FL? The role of autologous versus allogeneic transplant., American Society of Clinical Oncology Annual Meetings, Chicago, IL, 06/03/2019

Health Service Research – Malignant conditions (lymphoid disease): Treatment-based outcomes, American Society of Hematology, Orlando, FL, 12/07/2019

Higher TBI dose-intensity in Flu/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation., TCT Meetings, Orlando, FL, 02/2020

? Clinical autologous transplantation: Building better transplant platforms in lymphoid malignancies, Virtual American Society of Hematology Annual Meetings, San Diego, CA, 12/07/2020

ASTCT Practice Guidelines Update, Session Chair, 2021 Virtual TCT Meetings of ASTCT and CIBMTR, 02/05/2021

CAR T-cell therapy, current status and future, Saudi Society of Blood and Marrow Transplantation, Webinar Series, 02/06/2021

Transplantation and cell therapy in B-cell lymphomas., Society of Medical Oncology Pakistan, 2nd Annual Hematology Conference, Pakistan, 02/06/2021

DLBCL – A hard nut to crack, 8th Pakistan Society of Hematology Webinar, Karachi, Pakistan, 03/05/2021

How to sequence cell-based therapies in Mantle Cell Lymphoma, for 47th Annual Meeting of the European Society for Blood and Marrow Transplantation, Virtual, 03/16/2021

National

Evaluation of rabbit antithymocyte globulin dose-intensity in patients undergoing allogeneic stem cell transplantation following reduced intensity conditioning with fludarabine, busulfan and rATG, American Society for Bone Marrow Transplantation Tandem Meetings, Tampa, FL, 02/11/2009

Impact of conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation for refractory grade-III follicular and diffuse large B-cell lymphomas, American Society of Hematology Annual Meeting, Atlanta, GA, 12/10/2012

Effect of graft source and transplant conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation for refractory mantle cell lymphoma, American Society of Hematology Annual Meeting, Atlanta, GA, 12/10/2012

Prospective evaluation of a 'two-pronged' strategy of atorvastatin administration as acute graft-versus-host disease prophylaxis to both donors and recipients of matched related donor allogeneic hematopoietic cell transplantation, American Society for Bone Marrow Transplantation Tandem Meetings, Salt Lake City, UT, 02/14/2013

Association of reduced intensity conditioning allograft as the first transplant approach in relapsed/refractory grade 3 follicular lymphoma with improved outcomes in long-term survivors., American Society of Clinical Oncology Annual Meetings, Chicago, IL, 05/30/2015

Prospective, multicenter clinical trial of atorvastatin-based acute graft-versus-host-disease prophylaxis in recipients of HLA-matched related donor and matched unrelated donor allogeneic hematopoietic cell transplantation., American Society for Blood and Marrow Transplantation Tandem Meetings, Honolulu, HI, 02/19/2016

Beyond matched donors: Current options for allogeneic stem cell transplantation in lymphomas., 13th International Ullmann Chicago Lymphoma Symposium, Chicago, IL, 05/07/2016

Transplantation basics: Follicular lymphoma and DLBCL., Transplant Symposium for North America Educational Forum on Lymphoma, Chicago, IL, 10/29/2016

Barriers for autologous transplantation in non-Hodgkin lymphomas., Annual APPNA Hematology & Oncology Chapter meeting, Orlando, FL, 02/24/2017

Transplant and non-Hodgkin lymphoma: HSCT in select NHL subtypes., 2nd Annual APPNA Hematology & Oncology Chapter meeting, Salt Lake City, UT, 02/23/2018

Maintenance therapy after autologous HCT for Hodgkin lymphoma., 4th International Workshop on Biology, Prevention and Treatment of Relapse after Hematopoietic Cell Transplantation., Chicago, IL, 09/21/2018

Transplant and non-Hodgkin lymphoma: HSCT in select NHL subtypes., 3rd Annual APPNA Hematology & Oncology Chapter meeting, Houston, TX, 02/20/2019 - 02/24/2019

Precision medicine: incorporating into BMT CTN clinical trials., BMT CTN Coordinators, Transplantation and Cellular Therapy Meeting, Houston, TX, 02/20/2019 - 02/24/2019

Transplant and non-Hodgkin lymphoma: HSCT in select NHL subtypes., 3rd Annual APPNA Hematology & Oncology Chapter meeting, Houston, TX, 02/22/2019

Current treatment approaches in follicular lymphoma., Lymphoma Rounds, Coronado, CA, 06/11/2019

Autologous transplantation in lymphomas., 4th Annual Pakistan BMT & Cell Therapy Physician Meeting, Orlando, FL, 02/20/2020

Debate: How best to manage patients with relapsed mantle cell lymphoma? Cell-based therapies with AlloSCT or CAR-T?, Great Debates & Updates in Hematological Malignancies, Los Angeles, CA, 03/07/2020

MCW BMT & CT program's experience and recovery plan in COVID-19 epidemic, BMT CTN Steering Committee Meeting., Virtual, 06/19/2020

Debate: How best to manage patients with relapsed mantle cell lymphoma? Cell-based therapies with AlloSCT or CAR-T?, Virtual Great Debates & Updates in Hematological Malignancies, Chicago, IL, 08/29/2020

Fresh or cryopreserved: The impact of cryopreservation on post-transplant cyclophosphamide-based transplant outcomes., Virtual Be the Match One Forum, 11/06/2020

Autologous transplantation and patient selection in DLBCL, Virtual Midwest Cellular Conference, 11/14/2020

Changing landscape of transplantation in B-cell lymphomas., Virtual HCP-led Education on HCT & role in MM & NHL, 12/11/2020

Regional

GVHD-Hydra against allogeneic stem cell transplantation, Hematology & Oncology Grand Rounds Feist-Weiller Cancer Center, LSU Health Sciences Center, Shreveport, LA, 06/13/2008

The role of revlimid® (lenalidomide) in multiple myeloma, CSB Promotional Program, Logan Regional Medical Center, Charleston, WV, 04/01/2010

Blood and marrow transplantation for follicular lymphoma in the rituximab era, 20th Annual Fall Cancer Center Conference, Morgantown, WV, 10/29/2010

Clinical trial options for patients with lymphoid malignancies, WVOS Spring CME Membership Conference, Roanoke, WV, 04/13/2012

Immune Modulation for Preventing Graft-versus-Host Disease: Hope or Hype?, Case Western Reserve University Comprehensive Cancer Center, Cleveland, OH, 04/19/2013

Immune Modulation to Mitigate GVHD: The WV Experience, Medical College of Wisconsin Cancer Center, Milwaukee, WI, 05/30/2013

Classical Hodgkin lymphoma, Leukemia Lymphoma Society 2nd Annual Lymphoma Survivorship Conference, Milwaukee, WI, 04/05/2014

Therapeutic landscape of mantle cell lymphoma, Celgene District Meeting, Lake Geneva, WI, 06/09/2014

An update on transplantation for lymphoid malignancies, Fourth Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 03/07/2015

Hodgkin lymphoma, Leukemia Lymphoma Society 3rd Annual Lymphoma Survivorship Conference, Madison, WI, 05/09/2015

Advancing quality healthcare metrics through the personalization of treatment for the patients with chronic lymphocytic leukemia., Hospital Grand Rounds, Mount Sinai Hospital, Chicago, IL, 02/25/2016

Networking and research collaboration for hematologists/oncologists of Pakistani origin., 1st APPNA Hem-Onc Chapter ASCO Annual Meeting, Chicago, IL, 06/04/2016

Role of targeted therapies in the management of chronic lymphocytic leukemia: From clinical data to individualized care., Internal Medicine Grand Rounds, Mount Sinai Hospital, Chicago, IL, 08/17/2016

Non-Hodgkin lymphoma (NHL) - Low grade., Leukemia & Lymphoma Society, Blood Cancer Conference, Milwaukee, WI, 09/24/2016

Transplantation in advanced lymphomas: Indications in targeted therapy era., University of Cincinnati Grand Rounds, The Vontz Center for Molecular Studies, Cincinnati, OH, 09/30/2016

Transplantation for lymphoid malignancies: Relevance in 2016 and beyond., 26th Annual Fall Cancer Conference, at the West Virginia University, Morgantown, WV, 10/07/2016

Current role of autologous transplantation for non-Hodgkin lymphomas., Fox Valley Hematology & Oncology Grand Rounds, Appleton, WI, 02/08/2017

Basics of lymphoma for a statistician., CIBMTR Bi-Campus Statistician Meeting, Milwaukee, WI & Minneapolis, MN, 04/21/2017

Non-Hodgkin lymphoma (NHL) – High grade and Hodgkin lymphoma., Leukemia & Lymphoma Society, Blood Cancer Conference, Hayat Regency, Milwaukee, WI, 09/23/2017

Transplantation for B-cell NHL: Relevance in 2018 and beyond., Blood & Marrow Transplant and Cellular Immunotherapy Grand Rounds, Moffitt Cancer Center and Research Institute, 04/10/2018

Autologous transplantation for non-Hodgkin lymphomas., Methodist Hospital, Houston, TX, 06/28/2018

Transplantation for lymphoid malignancies: Breaking barriers, M.D. Anderson Cancer Center Apheresis Unit, Houston, TX, 06/29/2018

Transplantation for B-cell NHL: A registry researcher's perspective., Hematology Grand Rounds, Levine Cancer Institute, Charlotte, NC, 08/02/2018

Should Hodgkin lymphoma patients that fail autologous transplantation still undergo allogeneic transplant?, 8th Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 03/09/2019

Allogeneic stem cell transplant still has a role in Hodgkin lymphoma. (Debate Moderator), 16th International Ullmann Chicago Lymphoma Symposium, Chicago, IL, 04/13/2019

ADCs in Hodgkin and non-Hodgkin Lymphomas: Here to stay!, OncLive State of the Science Summit: Treatment of Hematological Malignancies, Brookfield, WI, 04/23/2019 - 08/22/2019

Transplant and cell therapy in B-cell NHL: Informing practice from a CIBMTR perspective., Special Hematological Malignancy Seminar at the Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX, 08/22/2019

Understanding mantle cell lymphoma (MCL): Current challenges and emerging treatment options, Arizona Oncology, Scottsdale, AZ, 11/20/2019

Evolving paradigms in the diagnosis and management of chronic lymphocytic leukemia., Mercy Walworth Oncology, Lake Geneva, WI, 03/03/2020

Transplant & cell therapies in B-NHL: Insights from CIBMTR data., Virtual Houston Methodist Cancer Center Oncology Grand Rounds, Houston, TX, 08/04/2020

Lymphoma: High grade., Virtual Leukemia & Lymphoma Society Blood Cancer Conference, Milwaukee, WI, 10/17/2020

Local

Allogeneic transplantation for chronic lymphocytic leukemia - From bedside to bench, Comprehensive Transplant Center Seminar, The Ohio State University Medical Center and Arthur G. James Comprehensive Cancer Center, Columbus, OH, 02/25/2009

CD103 deficiency Separates GVHD from GVL effects - Implications of murine solid organ & BMT models for stem cell transplantation in humans, Medicine Grand Rounds, West Virginia University, Morgantown, WV, 01/15/2010

T-cell trafficking and modulation of Graft-versus-Host Disease, Osborn Program Meeting, West Virginia University, Morgantown, WV, 02/12/2010

A clinical trial taken to the lab, First Annual Osborn Program Retreat, Morgantown, WV, 08/20/2010

Mary Babb Randolph Cancer Center initiative to increase patient accrual on therapeutic clinical trials, Cancer Clinical Trials 101 Meeting, West Virginia University, Morgantown, WV, 02/09/2011

Atorvastatin for the prophylaxis of acute Graft-versus-Host Disease, Osborn Program Meeting, Westvaco NRC, WV, 08/05/2011

Follicular lymphoma: The key to the cure is clinical trials, Medicine Grand Rounds, Morgantown, WV, 01/20/2012

Management of Transplant Eligible Myeloma Patients: West Virginia & 2013, Medicine Grand Rounds, West Virginia University, Morgantown, WV, 05/24/2013

Graft-versus-Host Disease. Ixazomib for chronic GvHD prophylaxis., Division of Hematology/Oncology Research Meeting, Milwaukee, WI, 07/17/2014

Planning observational research in Hematology & Oncology Fellowship., Hematology/Oncology Fellowship Program Research Day, Medical College of Wisconsin, Milwaukee, WI, 08/19/2016

Meet the Professor: Management of diffuse large B-cell lymphoma., Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH, 09/30/2016

Role of targeted therapies in the management of chronic lymphocytic leukemia: From clinical data to individualized care., CME, Brookfield, WI, 11/02/2016

Transplant and non-Hodgkin lymphoma., University of Illinois at Chicago Group Meeting, San Diego, CA, 12/04/2016

Mobilizing autologous stem cells: Is there on best method?, APP & RN Education Session, Medical College of Wisconsin, Milwaukee, WI, 08/10/2017

Allogeneic transplantation at advanced age., Research Seminar at the Division of Geriatrics/Gerontology, Zablocki VA Medical Center, Milwaukee, WI, 09/01/2017

Patient-specific overview of Hodgkin and non-Hodgkin lymphomas., Ask the Doctor Program by Lymphoma Research Foundation, Wisconsin Room, Hilton, Milwaukee, WI, 11/01/2017

Transplant and non-Hodgkin lymphoma. HSCT in select NHL subtypes., Advocate Lutheran General Hospital, Chicago, IL, 11/08/2017

Role of autologous stem cell transplantation in the treatment of non-Hodgkin lymphoma subtypes., Oak Brook, IL, 12/12/2018

ASCT for non-Hodgkin lymphomas., Dallas, TX, 08/21/2019

Changing landscape of cell therapies in B-cell NHL., BMT Conference at the Colorado Blood Cancer, Denver, CO, 08/30/2019

Mobilizing autologous stem cells: Is there on best method?, BMT & Cellular Therapy Program Education Session, Medical College of WI, Milwaukee, WI, 11/14/2019

Evolving paradigms in the diagnosis and management of chronic lymphocytic leukemia., Brookfield, WI, 12/03/2019

Diagnosis and management of CLL., Janesville, WI, 03/03/2020

Mantle cell lymphoma. Pathogenesis, management and future directions., Virtual Milwaukee Regional Practice Outreach Event., Milwaukee, WI, 12/16/2020

PEER REVIEWED WORKSHOPS/PRESENTATIONS:

Regional

Zaidi A, Hamadani M, Zahra K, Muazzam I, Shujaat A, Etiological Factors of Hepatocellular Carcinoma in South East Asia., Sixth Shaikat Khanum Memorial Cancer Hospital and Research Center Symposium, Dubai, 04/2003

Rehman S, Hamadani M, Awab A, Venkatappa S, Eichner ER, Fondaparinux as an alternative anticoagulant in Heparin induced thrombocytopenia. Report of two cases., American College of Physicians Oklahoma Chapter Scientific Meeting, 2004

Hamadani M, Awab A, Ali T, Granulocytic Sarcoma Presenting as Multiple Skeletal Lesions: A Case Report and Review of the Literature., American College of Physicians Oklahoma Chapter Scientific Meeting, 2004

Awab A, Hamadani M, Brown B, Peyton M, Bronchioloalveolar carcinoma with negative Positron Emission Tomography scan: A Case report and Review of the literature., American College of Physicians Oklahoma Chapter Scientific Meeting, 2004

Hamadani M, Benjamin M, Holla P, Selby G, Scofield H, Impact of Hyperglycemia on the Outcome of Bone Marrow Transplantation. A Retrospective Chart Review, American College of Physicians Oklahoma Chapter Scientific Meeting, 2004

Hamadani M, Kharfan-Dabaja M, Kamble R, Awab A, Kern W, Ozer H, Marginal Zone B-Cell Lymphoma of the Uterus: A Case Report and Review of the Literature., American College of Physicians Oklahoma Chapter Scientific Meeting, 2005

Hamadani M, Kamble R, Sethi S, Kharfan-Dabaja M, Kern W, Ozer H, Selby G, Elevated Mean Corpuscular Volume (MCV) following Autologous Hematopoietic Stem Cell Transplantation: Incidence and Significance., Stuart Wolf Day (Residents' Research Presentation Day), 2005

Hamadani M, Hays K, Patel S, Awab A, Tfayli A, McCune-Albright Syndrome presenting as Massive Pleural effusion. A Case Report and Review of the Literature., American College of Physicians Oklahoma Chapter Scientific Meeting, 2005

Hamadani M, Tfayli A, Kojouri K, Awab A, Comparison of Ondansetron, Granisetron, and Dolasetron with Dexamethasone in the prevention of Acute Nausea and Vomiting associated with Platinum-based therapy., Stuart Wolf Day (Residents' Research Presentation Day), 2005

- Hamadani M, Lightfoot S, Voskuhl G, Left Atrial Myxoma infected with Histoplasma., Stuart Wolf Day (Residents' Research Presentation Day), 2006
- Hamadani M, Liu K, Anthony BA, Gaughan A, Wang JJ, Shana'ah A, Johnson AJ, Byrd JC, Devine SM, Hadley GA, CD103 deficiency separates GVHD and GVL effects mediated by effector T-cells., OSU Comprehensive Cancer Center 11th Annual Scientific Meeting, 2009
- Davanzo L, Awan F, Hamadani M, Benson DM, Devine SM, Stem cell transplantation for peripheral T-cell lymphomas: Single-institution experience and outcomes., OSU Comprehensive Cancer Center 11th Annual Scientific Meeting, 2009

EXTRAMURAL TEACHING:

Medical Student Education

2010 - Present Medical Students in Hematology/BMT clinic (1 day/week)

Resident and Fellow Education

- 2009 - Present Continuity Fellows in Hematology/BMT clinic (1 day/week)
- 2009 - Present Hematology/BMT Fellow and Resident teaching (3-4 months/year)
- 2009 - Present Ambulatory Residents and Fellows in Hematology clinic (1.5 days/week)
- 2010 - 2013 Internal Medicine Resident Noon Lecture Series, Acute and Chronic Leukemias for Medicine Residents.
- 2010 - 2011 Internal Medicine Resident Noon Lecture Series, Hypereosinophilic syndrome: What an internist needs to know.
- 2010 - 2013 Cancer Pharmacology & Therapeutics Lecture Series for Cancer Cell Biology Graduate Students, Leukemia and lymphoma: Treatment options.
- 2011 - 2013 Internal Medicine Resident Noon Lecture Series, Basics of hematology for internal medicine boards.
- 2011 - 2013 Hematology & Oncology Fellows' Core Lecture Series, Current concepts in diagnosis and management of multiple myeloma.
- 2011 - 2013 Preceptor: Physical diagnosis and clinical integration I/II
- 2011 - 2013 Hematology & Oncology Fellows' Core Lecture Series, Current concepts in diagnosis and management of follicular lymphoma.
- 2011 - 2013 Internal Medicine Resident Noon Lecture Series, Myeloma and related disorders.
- 2011 - 2013 Hematology & Oncology Fellows' Core Lecture Series, Current concepts in diagnosis and management of chronic lymphocytic leukemia.
- 2011 - Present Hematology & Oncology Fellows' Core Lecture Series, Aggressive non-Hodgkin lymphomas.
- 2012 - Present Hematology & Oncology Fellows' Core Lecture Series, Classical Hodgkin lymphoma.
- 2014 - 2021 M1/M2 Clinical Apprenticeship Preceptor

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS

MENTORED:

Postdoctoral Researchers

- 2014 Ying Zhang, Member Dissertation Committee
- 2016 - 2017 Natasha Sahr, Doctoral Examination Committee

Clinical/Research Fellows

- 2010 Salman Osman, MD, ASBMT Travel Grant
- 2013 Lubna Chaudhary, Conquer Cancer Foundation of the ASCO Merit Award
- 2013 Sean Truong, 1st Place WVU-HSC GME Original Research Competition
- 2013 Sean Truong, Margaret J. Albrink research Award
- 2014 Binod Dhakal, Conquer Cancer Foundation of the ASCO Merit Award
- 2014 - 2016 Narendranath Epperla, MD, MS, Supervisor & MS Thesis Committee Member
- 2014 - 2016 Shamsudin Virani, MD, MS, Supervisor & MS Thesis Committee Member
- 2016 - 2018 Guru Murthy, MD, MS, Supervisor & MS Thesis Committee Member
- Abraham Kanate, Blood & Marrow Transplantation Fellowship, Stanford University

Faculty

2016 - 2017 Carla Casulo, MD, KL2 and Career Development, University of Rochester, Rochester, NY,
Award for Clinical and Translational Research

ELECTRONIC AND MEDIA:

- 05/31/2012 Advancing the care of myeloma and lymphoma patients and promoting access to clinical trials in the state of West Virginia. WBOY Channel 12 News. Morgantown, WV. <http://www.wboy.com/story/18670393/wvu-hospitals-begins-new-service-for-blood-cancer-patients>
- 06/30/2013 Ibrutinib: Pill could make chemotherapy a thing of the past. FOX Channel 10 News. Clarksburg, WV. <http://www.wdtv.com/wdtv.cfm?func=view&item=Pill-Could-Make-Chemotherapy-A-Thing-Of-The-Past10508>
- 2016 Classical Hodgkin lymphoma. Practical Medical Education and Science. 2016. <http://mededscience.com/presentations>
- 2016 Aggressive non-Hodgkin lymphoma. Practical Medical Education and Science. <http://mededscience.com/presentations>
- 2016 Role of transplantation in follicular and DLBCL. Practical Medical Education and Science. <https://youtu.be/IQX3HMoyU0w>
- 2016 Bone marrow transplant: A refresher. <http://bit.ly/2fAfXLd>
- 2017 How I manage: Hematopoietic cell transplantation in follicular lymphoma. 2017. <http://www.clinicaloncology.com/Hematologic-Malignancies/Article/09-17/How-I-Manage-Hematopoietic-Cell-Transplantation-in-Follicular-Lymphoma/44492>
- 06/10/2018 Hematopoietic cell transplantation for follicular lymphoma. A conversation with Mehdi Hamadani, MD. The ASCO Post. <http://www.ascopost.com/issues/june-10-2018/hematopoietic-cell-transplantation-for-follicular-lymphoma/>
- 12/2018 What to expect at the 60th ASH Annual Meeting with Drs. Hamadani, Sekeres, and Sola-Visne. The Hematologist 2018 ASH Podcast. https://soundcloud.com/ash_hematology/what-to-expect-at-the-60th-ash-annual-meeting-with-drs-hamadani-sekeres-and-sola-visner
- 01/2019 - 02/2019 60th ASH Annual Meeting wrap-up: A game changer in San Diego. The Hematologist. January-February 2019, Volume 16, Issue 1. <https://buff.ly/2sapu22>
- 04/06/2020 COVID-19 & Stem Cell Graft Cryopreservation: What's the Fuss About? <https://nucleus.astct.org/Full-Article/ArtMID/393/ArticleID/56/COVID-19-and-Stem-Cell-Graft-Cryopreservation-What%e2%80%99s-the-Fuss-About>
- 04/15/2020 COVID-19 Effect on Transplantation for Patients with Hematologic Malignancies. <https://www.oncnet.com/videos/covid-19-effect-transplantation-patients-hematologic-malignancies>
- 04/21/2020 COVID-19 and Cancer Care. The ASCO Post. <https://www.ascopost.com/videos/covid-19-and-cancer-care/mehdi-hamadani-on-delaying-autologous-transplant-in-patients-with-dlbcl-during-the-pandemic/>
- 04/28/2020 Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL. Oncology Learning Network. <https://www.oncnet.com/videos/benefits-and-risks-cell-therapies-relapsedrefractory-mcl>
- 03/18/2021 What are the options for cell-based therapies in mantle cell lymphoma? LymphomaHub. <https://lymphomahub.com/medical-information/what-are-the-options-for-cell-based-therapies-in-mantle-cell-lymphoma>

GRANT REVIEWER:

- 2010 - Present Thrasher Research Fund
2011 - Present FDA Orphan Products Research Project Grant (RO1)

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. **Hamadani M**, Kharfan-Dabaja M, Kamble R, Awab A, William K, Ozer H Primary Malignant Lymphoma of the Uterus. An Extranodal Lymphoma with an Ominous Five Year Survival. Pakistan Journal of Radiology. 2004 October-December;15(4):11-17
2. **Hamadani M**, Tfayli A, Sethi S, Awab A, Hamdani N. Granulocytic sarcoma manifesting as multiple skeletal lesions. Am J Med Sci. 2005 Sep;330(3):139-43.
3. Kamble RT, **Hamadani M**, Selby GB. Increased mean corpuscular volume after autologous hematopoietic

- stem cell transplantation: incidence and significance. *Biol Blood Marrow Transplant.* 2006 Jan;12(1):111-2.
4. Kamble RT, **Hamadani M**, Selby GB. Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. *J Antimicrob Chemother.* 2006 Apr;57(4):795-6.
 5. **Hamadani M**, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H. Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. *J Okla State Med Assoc.* 2006 Apr;99(4):154-6.
 6. **Hamadani M**, Awab A, Rashid A, Ali T, Brown B. Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. *J Coll Physicians Surg Pak.* 2006 May;16(5):376-7.
 7. **Hamadani M**, Awab A, Chaudhary L, Tfayli A. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. *J Oncol Pharm Pract.* 2006 Jun;12(2):67-8.
 8. Awab A, **Hamadani M**, Sud B, Voskuhl GW. Infected atrial myxoma. *Med J Aust.* 2006 Sep 18;185(6):332.
 9. Awab A, **Hamadani M**, Saya S, Whitsett T. Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography. *South Med J.* 2006 Oct;99(10):1142.
 10. **Hamadani M**, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. *J Oncol Pharm Pract.* 2006 Dec;12(4):237-9.
 11. Tfayli A, Selby G, Maqbool F, Bierbaum W, **Hamadani M**. Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. *Am J Hematol.* 2006 Dec;81(12):959-62.
 12. **Hamadani M**, Chaudhary L. McCune-Albright syndrome. *Med J Aust.* 2006 Dec 4-18;185(11-12):597.
 13. **Hamadani M**, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC. Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. *Bone Marrow Transplant.* 2007 Feb;39(4):249-51.
 14. Ali T, Hasan M, **Hamadani M**, Harty RF. Gastroparesis. *South Med J.* 2007 Mar;100(3):281-6.
 15. Awan F, **Hamadani M**. Gastrointestinal chronic graft-versus-host disease: management options. *J Oncol Pharm Pract.* 2007 Mar;13(1):49-51.
 16. **Hamadani M**, Benson DM Jr, Copelan EA. Thalidomide-induced fulminant hepatic failure. *Mayo Clin Proc.* 2007 May;82(5):638.
 17. **Hamadani M**, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? *J Oncol Pharm Pract.* 2007 Jun;13(2):69-75.
 18. Awan F, **Hamadani M**, Devine S. Paraneoplastic Sweet's syndrome and the pathergy phenomenon. *Ann Hematol.* 2007 Aug;86(8):613-4.
 19. Rashid A, Afaq A, **Hamadani M**, Warrach J, Hennebry T. An unusual etiology of chest pain. *J Okla State Med Assoc.* 2007 Sep;100(9):352-3.
 20. Awab A, **Hamadani M**, Peyton M, Brown B. False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. *Am J Med Sci.* 2007 Oct;334(4):311-3.
 21. Vrindavanam N, **Hamadani M**, Steele B, Awan F, Suster S, Benson DM Jr. Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. *Am J Hematol.* 2007 Dec;82(12):1120-1.
 22. **Hamadani M**, Magro CM, Porcu P. CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). *Br J Haematol.* 2008 Jan;140(2):122.
 23. **Hamadani M**, Benson DM Jr, Blum W, Garzon R, Devine SM. Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. *Transpl Infect Dis.* 2008 Feb;10(1):24-6.
 24. **Hamadani M**, Hade E, Benson DM Jr, Hofmeister CC. The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. *Biol Blood Marrow Transplant.* 2008 Mar;14(3):351-2.
 25. **Hamadani M**, Kraut EH. Review: isolated skeletal involvement in hairy cell leukemia. *Clin Adv Hematol Oncol.* 2008 Apr;6(4):294-6.
 26. **Hamadani M**, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. *Biol Blood Marrow Transplant.* 2008 Apr;14(4):480-3.
 27. **Hamadani M**, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. *Blood.* 2008 Apr 01;111(7):3901-2.
 28. **Hamadani M**, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. *Biol Blood Marrow Transplant.* 2008 May;14(5):556-67.

29. **Hamadani M**, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. *Biol Blood Marrow Transplant*. 2008 Jul;14(7):783-9. PMID: PMC4100722
30. **Hamadani M**, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2008 Oct;49(10):1893-8.
31. Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, **Hamadani M**, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzone M. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? *J Clin Oncol*. 2008 Nov 01;26(31):5134-6; author reply 5136-7.
32. **Hamadani M**, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. *Eur J Haematol*. 2008 Dec;81(6):425-31.
33. **Hamadani M**, Blum W Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. *Clinical Leukemia*. **Hamadani M.**, Blum W.: "Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia." *Clinical Leukemia*. 2009 February;3(1):47-57
34. Blum KA, **Hamadani M**, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. 2009 Mar;50(3):349-56. PMID: PMC3695225
35. **Hamadani M**, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. *Biol Blood Marrow Transplant*. 2009 May;15(5):547-53. PMID: PMC3953134
36. **Hamadani M**, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. *Blood*. 2009 Sep 17;114(12):2564-6.
37. **Hamadani M**, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. *Biol Blood Marrow Transplant*. 2009 Nov;15(11):1422-30. PMID: PMC3953136
38. Pant S, **Hamadani M**, Dodds AJ, Szer J, Crilly PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. *Br J Haematol*. 2010 Feb;148(4):623-6.
39. Benson DM Jr, Panzner K, **Hamadani M**, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. *Leuk Lymphoma*. 2010 Feb;51(2):243-51. PMID: PMC3557809
40. **Hamadani M**, Awan F, Villalona-Calero MA. Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. *Am J Clin Oncol*. 2010 Feb;33(1):109.
41. **Hamadani M**, Awan FT. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. *Hematol Oncol*. 2010 Mar;28(1):3-12.
42. **Hamadani M**, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2010 Aug;45(8):1259-68.
43. Christian B, Zhao W, **Hamadani M**, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. *J Clin Oncol*. 2010 Nov 01;28(31):e629-32.
44. **Hamadani M**, Craig MD, Gibson LF, Remick SC. The evolving role of statins in hematopoietic stem and progenitor cell transplantation. *Am J Blood Res*. 2011;1(1):57-64. PMID: PMC3301410
45. Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, **Hamadani M**. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. *Hematol Oncol Stem Cell Ther*. 2011;4(4):149-56.
46. Liu K, Anthony BA, Yearsly MM, **Hamadani M**, Gaughan A, Wang JJ, Devine SM, Hadley GA. CD103

- deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. *PLoS One*. 2011;6(7):e21968. PMID: PMC3136479
47. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, **Hamadani M**, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. *Blood*. 2011 Aug 18;118(7):1979-88. PMID: PMC3158724
 48. **Hamadani M**, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. *Cancer Control*. 2011 Oct;18(4):237-45.
 49. **Hamadani M**, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. *Hematol Oncol*. 2011 Dec;29(4):202-10. PMID: PMC3557914
 50. Chaudhary L, **Hamadani M** Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies. *Journal of Blood Disorders & Transfusion*. Chaudhary L, **Hamadani M** (2012) Management Strategies for Follicular Lymphoma patients in Remission after Modern Frontline Chemoimmunotherapies. *J Blood Disorders Transf* 3:e105
 51. Kanate AS, Kharfan-Dabaja MA, **Hamadani M**. Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. *Bone Marrow Res*. 2012;2012:897215. PMID: PMC3477524
 52. Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, **Hamadani M**. Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. *J Oncol*. 2012;2012:931071. PMID: PMC3335320
 53. Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, **Hamadani M**. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. *Bone Marrow Transplant*. 2012 Jan;47(1):146-8.
 54. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, **Hamadani M**, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R. Regulation of acute graft-versus-host disease by microRNA-155. *Blood*. 2012 May 17;119(20):4786-97. PMID: PMC3367879
 55. **Hamadani M**, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. *Biol Blood Marrow Transplant*. 2012 Jul;18(7):1128-35.
 56. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, **Hamadani M**, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. *Biol Blood Marrow Transplant*. 2012 Sep;18(9):1446-54. PMID: PMC3499973
 57. Ross AL, Slain D, Cumpston A, Bryant AM, **Hamadani M**, Craig M. Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. *Int J Antimicrob Agents*. 2012 Dec;40(6):557-61.
 58. Sweet MA, Cumpston A, Briggs F, Craig M, **Hamadani M**. Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. *Am J Infect Control*. 2012 Dec;40(10):931-4.
 59. Kharfan-Dabaja MA, **Hamadani M**, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. *J Hematol Oncol*. 2013 Jan 04;6:2. PMID: PMC3548722
 60. Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, **Hamadani M**. Incidence and Pattern of

- Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. *Bone Marrow Res.* 2013;2013:414959. PMID: PMC3652129
61. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, **Hamadani M**, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant.* 2013 Feb;19(2):173-9. PMID: PMC3553321
 62. Cumpston A, Craig M, **Hamadani M**, Abraham J, Hobbs GR, Sarwari AR. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. *Transpl Infect Dis.* 2013 Apr;15(2):142-9.
 63. **Hamadani M**, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant.* 2013 Apr;19(4):625-31. PMID: PMC3640440
 64. **Hamadani M**, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. *Biol Blood Marrow Transplant.* 2013 May;19(5):746-53. PMID: PMC3650915
 65. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, **Hamadani M**. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2013 Jul;19(7):1006-12.
 66. Kanate AS, Watkins K, Cumpston A, Craig M, **Hamadani M**. Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. *Biol Blood Marrow Transplant.* 2013 Jul;19(7):1133-5.
 67. **Hamadani M**. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? *Bone Marrow Transplant.* 2013 Aug;48(8):1013-21.
 68. Kharfan-Dabaja MA, Nishihori T, Otrrock ZK, Haidar N, Mohty M, **Hamadani M**. Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2013 Sep;19(9):1288-300.
 69. **Hamadani M**, Kanate AS Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. *Community Oncology.* **Hamadani M.**, Kanate AS.: "Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas." *Community Oncology.* 2013 October;10(10):279-281
 70. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, **Hamadani M**. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. *Bone Marrow Transplant.* 2013 Oct;48(10):1279-84.
 71. Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, **Hamadani M**. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. *J Clin Apher.* 2013 Oct;28(5):359-67.
 72. Chaudhary L, Kharfan-Dabaja MA, Hari P, **Hamadani M**. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? *Bone Marrow Transplant.* 2013 Nov;48(12):1489-96.
 73. Kharfan-Dabaja MA, **Hamadani M**, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. *Br J Haematol.* 2013 Nov;163(3):315-25.
 74. Palla AR, **Hamadani M**. Rituximab maintenance versus retreatment in follicular lymphoma. *Hematol Oncol.* 2013 Dec;31(4):171-8.
 75. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, **Hamadani M**, Inamoto Y, Kamble RT,

- Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. *Blood*. 2013 Dec 05;122(24):3863-70. PMID: PMC3854108
76. **Hamadani M**, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. *J Clin Oncol*. 2013 Dec 10;31(35):4416-23. PMID: PMC3842909
77. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, **Hamadani M**, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. 2014 Jan;20(1):89-97. PMID: PMC3886623
78. **Hamadani M**, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. *Semin Hematol*. 2014 Jan;51(1):73-86.
79. Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, **Hamadani M**. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. *Clin Lymphoma Myeloma Leuk*. 2014 Feb;14(1):50-5.
80. Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, **Hamadani M**. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. *Clin Lymphoma Myeloma Leuk*. 2014 Feb;14(1):50-5.
81. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, **Hamadani M**, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. *J Clin Oncol*. 2014 Feb 01;32(4):273-81. PMID: PMC3897255
82. **Hamadani M**. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplant? *Biol Blood Marrow Transplant*. 2014 Mar;20(3):292-4.
83. Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, **Hamadani M**, Kanate AS. Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2014 Mar;20(3):415-20. PMID: PMC4557764
84. Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, **Hamadani M**, Cumpston A. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. *Ann Hematol*. 2014 Apr;93(4):677-82.
85. Kanate AS, Pasquini MC, Hari PN, **Hamadani M**. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. *World J Stem Cells*. 2014 Apr 26;6(2):69-81. PMID: PMC3999783
86. Kharfan-Dabaja MA, **Hamadani M**, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! *Bone Marrow Transplant*. 2014 May;49(5):599-606.
87. Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerme G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2014 May;20(5):646-54.
88. Michaelis LC, **Hamadani M**, Hari PN. Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. *Expert Rev Hematol*. 2014 Jun;7(3):321-4.
89. **Hamadani M**, Vos JA, Craig MD. Reply to S. Fuji et al. *J Clin Oncol*. 2014 Jun 10;32(17):1860-1.
90. Wirk B, Fenske TS, **Hamadani M**, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski

- JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. *Biol Blood Marrow Transplant.* 2014 Jul;20(7):951-9. PMID: PMC4060436
91. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, **Hamadani M**, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ. Allogeneic transplantation for patients age \geq 40 years with non-Hodgkin lymphoma: encouraging progression-free survival. *Biol Blood Marrow Transplant.* 2014 Jul;20(7):960-8. PMID: PMC4057955
92. **Hamadani M**, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2014 Nov;20(11):1729-36. PMID: PMC4194275
93. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, **Hamadani M**, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncol.* 2014 Dec;15(13):1503-1512.
94. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobycki W, Rizzo JD, Hari PN, **Hamadani M**. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. *Biol Blood Marrow Transplant.* 2014 Dec;20(12):1926-31.
95. **Hamadani M**. Autologous hematopoietic cell transplantation: an update for clinicians. *Ann Med.* 2014 Dec;46(8):619-32.
96. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, **Hamadani M**, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. *Biol Blood Marrow Transplant.* 2015 Mar;21(3):552-8. PMID: PMC4329042
97. Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, **Hamadani M**, Hari PN. Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. *Bone Marrow Transplant.* 2015 Mar;50(3):449-51.
98. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, **Hamadani M**. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. *Clin Lymphoma Myeloma Leuk.* 2015 Apr;15(4):199-207.
99. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, **Hamadani M**. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. *Bone Marrow Transplant.* 2015 Apr;50(4):610-2.
100. Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, **Hamadani M**, Tse WW, Lazarus HM. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. *Clin Lymphoma Myeloma Leuk.* 2015 Jul;15(7):428-432.e2. PMID: PMC4484305
101. Shah N, Callander N, Ganguly S, Gul Z, **Hamadani M**, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA,

- Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015 Jul;21(7):1155-66.
102. Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, **Hamadani M**, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Secondary solid cancer screening following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Aug;50(8):1013-23. PMID: PMC4989866
103. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, **Hamadani M**, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. *Bone Marrow Transplant*. 2015 Aug;50(8):1057-62. PMID: PMC4527880
104. Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, **Hamadani M**, Craig M, Kanate AS. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. *Antimicrob Agents Chemother*. 2015 Aug;59(8):4424-8. PMID: PMC4505228
105. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, **Hamadani M**, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2015 Sep;21(9):1605-11. PMID: PMC4558181
106. Epperla N, Fenske TS, Hari PN, **Hamadani M**. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. *World J Transplant*. 2015 Sep 24;5(3):81-8. PMID: PMC4580930
107. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, **Hamadani M**, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. *Biol Blood Marrow Transplant*. 2015 Oct;21(10):1746-53. PMID: PMC4568162
108. **Hamadani M**, Balasubramanian S, Hari PN. Ibrutinib in Refractory Classic Hodgkin's Lymphoma. *N Engl J Med*. 2015 Oct;373(14):1381-2.
109. Epperla N, Fenske TS, Lazarus HM, **Hamadani M**. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? *Bone Marrow Transplant*. 2015 Nov;50(11):1393-404.
110. Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, **Hamadani M**. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. *Bone Marrow Transplant*. 2015 Nov;50(11):1416-23. PMID: PMC4633349
111. Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, **Hamadani M**, D'Souza A. Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. *Am J Hematol*. 2015 Nov;90(11):E212-3. PMID: PMC4618044
112. Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, **Hamadani M**, Kanate AS. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. *Cytotherapy*. 2015 Dec;17(12):1785-92. PMID: PMC4700501

113. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, **Hamadani M**. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. *Biol Blood Marrow Transplant*. 2015 Dec;21(12):2091-2099. PMID: PMC4639453
114. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, **Hamadani M**, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Dec;50(12):1513-8. PMID: PMC4548821
115. Nishihori T, Al-Kadhimi Z, **Hamadani M**, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. *Immunotherapy*. 2016;8(4):435-47.
116. Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, **Hamadani M**, Petros W. Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. *Antimicrob Agents Chemother*. 2016 Jan 11;60(3):1830-3. PMID: PMC4775958
117. Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, **Hamadani M**. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. *Bone Marrow Transplant*. 2016 Jan;51(1):58-66. PMID: PMC4703480
118. Nelson AA, Harrington AM, Kroft S, Dahar MA, **Hamadani M**, Dhakal B. Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. *Bone Marrow Transplant*. 2016 Feb;51(2):300-2.
119. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, **Hamadani M**. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. *Blood*. 2016 Feb 18;127(7):938-47. PMID: PMC4760094
120. Kharfan-Dabaja MA, El-Asmar J, Awan FT, **Hamadani M**, Ayala E. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. *Best Pract Res Clin Haematol*. 2016 Mar;29(1):54-66.
121. Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, **Hamadani M**, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. *Am J Hematol*. 2016 Mar;91(3):322-9. PMID: PMC4764423
122. El-Asmar J, Reljic T, Ayala E, **Hamadani M**, Nishihori T, Kumar A, Kharfan-Dabaja MA. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. *Biol Blood Marrow Transplant*. 2016 May;22(5):802-14.
123. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Aziz H, Malone A, Olsson R, **Hamadani M**, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijjiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. *Biol Blood Marrow Transplant*. 2016 Jun;22(6):1056-1064. PMID: PMC4877686
124. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, **Hamadani M**, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma:

- Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. *Clin Lymphoma Myeloma Leuk*. 2016 Jul;16(7):379-86.
125. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, **Hamadani M**. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. *Br J Haematol*. 2016 Jul;174(2):235-48. PMID: PMC4940282
126. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, **Hamadani M**, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1493-1503. PMID: PMC4949101
127. Fenske TS, **Hamadani M**, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. *Biol Blood Marrow Transplant*. 2016 Sep;22(9):1543-1551. PMID: PMC4981559
128. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, **Hamadani M**. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. *J Clin Oncol*. 2016 Sep 10;34(26):3141-9. PMID: PMC5012706
129. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, **Hamadani M**. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. *J Oncol Pharm Pract*. 2016 Oct;22(5):666-78.
130. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, **Hamadani M**. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2016 Oct;22(10):1773-1780.
131. Snyder M, Shillingburg A, Newton M, **Hamadani M**, Kanate AS, Craig M, Cumpston A. Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. *Support Care Cancer*. 2016 Oct;24(10):4237-40.
132. Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, **Hamadani M**, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. *Cancer*. 2016 Oct;122(19):3005-3014. PMID: PMC5030151
133. Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, **Hamadani M**, Kumar A. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. *Future Oncol*. 2016 Nov;12(22):2631-2642.
134. Epperla N, Shah N, **Hamadani M**, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2016 Dec;16(12):672-678.
135. Kharfan-Dabaja MA, Kumar A, **Hamadani M**, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorrow M,

- Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2016 Dec;22(12):2117-2125. PMID: PMC5116249
136. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, **Hamadani M**. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplant.* 2016 Dec;51(12):1602-1604.
137. Epperla N, Olteanu H, **Hamadani M**. Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. *Br J Haematol.* 2016 Dec;175(5):758.
138. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, **Hamadani M**, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. *Biol Blood Marrow Transplant.* 2017 Jan;23(1):60-66. PMID: PMC5182098
139. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, **Hamadani M**. Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. *Bone Marrow Transplant.* 2017 Jan;52(1):147-150.
140. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, **Hamadani M**, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant.* 2017 Feb;23(2):269-277. PMID: PMC5346183
141. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, **Hamadani M**, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. *Bone Marrow Transplant.* 2017 Feb;52(2):173-182. PMID: PMC5288134
142. Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, **Hamadani M**, Kanate AS, Cumpston A. Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). *Bone Marrow Transplant.* 2017 Feb;52(2):321-322.
143. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, **Hamadani M**. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. *Am J Hematol.* 2017 Feb;92(2):161-170. PMID: PMC5549936
144. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, **Hamadani M**, Pasquini M, D'Souza A, Hari P. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. *Clin Lymphoma Myeloma Leuk.* 2017 Mar;17(3):165-172.
145. Guru Murthy GS, **Hamadani M**, Bhatt VR, Dhakal I, Mehta P. Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. *Clin Lymphoma Myeloma Leuk.* 2017 Apr;17(4):201-206.
146. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, **Hamadani M**, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. *J Clin Oncol.* 2017 Apr 10;35(11):1154-1161. PMID: PMC5455603

147. Epperla N, **Hamadani M**, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. *Br J Haematol*. 2018 Jun;181(5):703-706.
148. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, **Hamadani M**. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. *Clin Lymphoma Myeloma Leuk*. 2017 May;17(5):305-311.e2.
149. Liu HD, Ahn KW, Hu ZH, **Hamadani M**, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biol Blood Marrow Transplant*. 2017 May;23(5):767-775. PMID: PMC5590102
150. **Hamadani M**, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*. 2017 May;23(5):853-856. PMID: PMC5410937
151. Jethava Y, Guru Murthy GS, **Hamadani M**. Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? *Hematol Oncol Stem Cell Ther*. 2017 Jun;10(2):47-56.
152. Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, **Hamadani M**, Hari P. Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Jun;23(6):952-957.
153. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, **Hamadani M**. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. *J Hematol Oncol*. 2017 Jun 12;10(1):117. PMID: PMC5469142
154. Shillingburg A, Kanate AS, **Hamadani M**, Wen S, Craig M, Cumpston A. Treatment of severe mucositis pain with oral ketamine mouthwash. *Support Care Cancer*. 2017 Jul;25(7):2215-2219. PMID: PMC5500907
155. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, **Hamadani M**, Karmali R, Fenske TS. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17(7):408-414.
156. Haverkos BM, Abbott D, **Hamadani M**, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. *Blood*. 2017 Jul 13;130(2):221-228. PMID: PMC5510790
157. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, **Hamadani M**. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1295-1302.
158. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlag N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, **Hamadani M**. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. *Br J Haematol*. 2018 Sep;182(6):916-920. PMID: PMC5796874
159. Hammons L, Brazauskas R, Pasquini M, **Hamadani M**, Hari P, D'Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. *Hematol Oncol Stem Cell Ther*. 2018 Jun;11(2):105-111.
160. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, **Hamadani M**, Hari P. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with

- multiple myeloma in the United States, 2004-2014. *Leukemia*. 2017 Sep;31(9):1998-2000. PMID: PMC5587375
161. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, **Hamadani M**, Fenske TS, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. *Am J Hematol*. 2017 Sep;92(9):E563-E565.
162. Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, **Hamadani M**, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. *J Clin Oncol*. 2017 Sep 10;35(26):3002-3009. PMID: PMC5590802
163. Jerkins JH, **Hamadani M**, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. *Am J Hematol*. 2017 Oct;92(10):E610-E611.
164. Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, **Hamadani M**, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. *Haematologica*. 2017 Oct;102(10):1767-1775. PMID: PMC5622861
165. Kharfan-Dabaja MA, Kumar A, Ayala E, **Hamadani M**, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2017 Nov;23(11):1826-1838.
166. Epperla N, Hemauer K, **Hamadani M**, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. *Transfusion*. 2017 Nov;57(11):2775-2781.
167. Thompson J, Yin Z, D'Souza A, Fenske T, **Hamadani M**, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. *Biol Blood Marrow Transplant*. 2017 Nov;23(11):1955-1960.
168. Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, **Hamadani M**. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? *Bone Marrow Transplant*. 2017 Nov;52(11):1487-1494.
169. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, **Hamadani M**, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). *J Hematol Oncol*. 2017 Nov 02;10(1):171. PMID: PMC5668956
170. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, **Hamadani M**, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. *Cancer*. 2017 Nov 15;123(22):4411-4418.
171. D'Souza A, Flynn K, Chhabra S, Dhakal B, **Hamadani M**, Jacobsen K, Pasquini M, Weihrauch D, Hari P. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. *Contemp Clin Trials Commun*. 2017 Dec;8:33-38. PMID: PMC5898504
172. Epperla N, **Hamadani M**. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. *Hematol Oncol Stem Cell Ther*. 2017 Dec;10(4):277-284.
173. **Hamadani M**, Horowitz MM. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit

- All? J Oncol Pract. 2017 Dec;13(12):798-806. PMID: PMC5728364
174. Epperla N, **Hamadani M**, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. *Hematol Oncol*. 2017 Dec;35(4):528-535.
 175. Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, **Hamadani M**, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. *Br J Haematol*. 2017 Dec;179(5):781-789.
 176. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, **Hamadani M**. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. *Biol Blood Marrow Transplant*. 2018 Jan;24(1):78-85. PMID: PMC5743624
 177. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, **Hamadani M**, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. *Br J Haematol*. 2018 Feb;180(4):534-544.
 178. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, **Hamadani M**, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018 Feb;24(2):228-241. PMID: PMC5768142
 179. McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, **Hamadani M**, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. *Blood Adv*. 2018 Feb 13;2(3):299-307. PMID: PMC5812334
 180. Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, **Hamadani M**, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. *Cancer*. 2018 Feb 15;124(4):816-825. PMID: PMC5871233
 181. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, **Hamadani M**, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. *Biol Blood Marrow Transplant*. 2018 Mar;24(3):478-485. PMID: PMC5826888
 182. Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, **Hamadani M**, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. *Biol Blood Marrow Transplant*. 2018 Mar;24(3):486-493.
 183. Dhakal B, Szabo A, Chhabra S, **Hamadani M**, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Mar 01;4(3):343-350. PMID: PMC5885822

184. Shah NN, Fenske TS, **Hamadani M**, Svoboda J. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. *Br J Haematol*. 2019 Mar;184(5):838-840.
185. Brown JR, **Hamadani M**, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. *Lancet Haematol*. 2018 Apr;5(4):e170-e180. PMID: PMC7029813
186. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, **Hamadani M**, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. *Haematologica*. 2018 Apr;103(4):717-727. PMID: PMC5865423
187. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, **Hamadani M**, Pasquini MC. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. *Cancer*. 2018 Apr 15;124(8):1733-1742. PMID: PMC5946312
188. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, **Hamadani M**. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. *Blood Adv*. 2018 Apr 24;2(8):933-940. PMID: PMC5916010
189. Epperla N, **Hamadani M**, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 May;24(5):983-988.
190. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, **Hamadani M**, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant*. 2018 May;53(5):535-555. PMID: PMC5985976
191. Reza Hosseini O, Hanaei S, **Hamadani M**, Keshavarz-Fathi M, Rezaei N. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. *Int Rev Immunol*. 2018 May 04;37(3):165-173.
192. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, **Hamadani M**, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. *BMC Cancer*. 2018 May 24;18(1):593. PMID: PMC5968588
193. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, **Hamadani M**, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. *Biol Blood Marrow Transplant*. 2018 Jun;24(6):1119-1124.
194. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, **Hamadani M**. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

- Biol Blood Marrow Transplant. 2018 Jun;24(6):1163-1171. PMID: PMC5993598
195. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, **Hamadani M**, Park SI, Flowers CR, Cohen JB. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. *Cancer*. 2018 Jun 01;124(11):2306-2315. PMID: PMC5992038
 196. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, **Hamadani M**. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. *Cancer*. 2018 Jun 15;124(12):2541-2551. PMID: PMC5990449
 197. Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, **Hamadani M**, Tamari R, Anderton K, Dixon P, Giralt SA. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. *Biol Blood Marrow Transplant*. 2018 Jul;24(7):1379-1385. PMID: PMC7590532
 198. Dhakal B, D'Souza A, Lakshman A, **Hamadani M**, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Aug;24(8):1610-1614.
 199. Raj RV, **Hamadani M**, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. *Biol Blood Marrow Transplant*. 2018 Aug;24(8):1664-1670.
 200. Guru Murthy GS, **Hamadani M**, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy related myeloid neoplasm in United States. *Leuk Res*. 2018 Aug;71:95-99.
 201. Sureda A, Montoto S, Dreger P, **Hamadani M**, Pasquini MC. Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. *Cancer*. 2018 Aug;124(16):3455-3456.
 202. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, **Hamadani M**, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. *Bone Marrow Transplant*. 2018 Sep;53(9):1210-1213.
 203. Hashmi H, **Hamadani M**, Awan FT. Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. *Expert Opin Pharmacother*. 2018 Oct;19(15):1631-1634.
 204. **Hamadani M**. Advances in Transplantation for Lymphomas Resulting from CIBMTR Lymphoma Working Committee's Research Portfolio: A Five-Year Report (2013-2018). *Adv Cell Gene Ther*. 2018 Nov;1(3). PMID: PMC7946113
 205. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, **Hamadani M**, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. *Leuk Res*. 2018 Nov;74:130-136. PMID: PMC6219911
 206. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, **Hamadani M**, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. *Leuk Lymphoma*. 2018 Dec;59(12):2862-2870. PMID: PMC6360945
 207. Voshtina E, Szabo A, **Hamadani M**, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. *Biol Blood Marrow Transplant*. 2019 Jan;25(1):e33-e38.

208. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, **Hamadani M**. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. *J Hematol Oncol*. 2019 Jan 10;12(1):6. PMID: PMC6329157
209. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, **Hamadani M**, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. *Clin Lymphoma Myeloma Leuk*. 2019 Feb;19(2):95-102.
210. Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schmid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominiotto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbaz Z, **Hamadani M**. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. *Blood Adv*. 2019 Feb 12;3(3):360-369. PMID: PMC6373757
211. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, **Hamadani M**, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. *Blood Adv*. 2019 Mar 26;3(6):875-883. PMID: PMC6436017
212. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, **Hamadani M**. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):827-833.
213. Badar T, **Hamadani M**, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. *Leuk Lymphoma*. 2019 Apr;60(4):940-946.
214. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, **Hamadani M**. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. *JAMA Oncol*. 2019 May 01;5(5):715-722. PMID: PMC6988125
215. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, **Hamadani M**, Ahmed S, Cashen AF, Fenske TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. *Blood Adv*. 2019 Jun 11;3(11):1661-1669. PMID: PMC6560348
216. Rashidi A, **Hamadani M**, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv*. 2019 Jun 25;3(12):1826-1836. PMID: PMC6595262
217. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, **Hamadani M**, Chhabra S. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1456-1464.

218. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, **Hamadani M**, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. *Leukemia*. 2019 Jul;33(7):1736-1746. PMID: PMC6755968
219. Kumar A, Reljic T, **Hamadani M**, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. *Bone Marrow Transplant*. 2019 Jul;54(7):1094-1106.
220. Levis MJ, Chen YB, **Hamadani M**, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network. FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? *J Clin Oncol*. 2019 Jul 01;37(19):1604-1607. PMID: PMC6804888
221. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, **Hamadani M**. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. *JAMA Netw Open*. 2019 Jul 03;2(7):e196476.
222. Dhakal B, D'Souza A, **Hamadani M**, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. *Blood Cancer J*. 2019 Jul 29;9(8):56. PMID: PMC6663939
223. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, **Hamadani M**, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2019 Aug;25(8):1492-1497.
224. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, **Hamadani M**. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Aug;25(8):1689-1694.
225. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, **Hamadani M**, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. *Clin Cancer Res*. 2019 Aug 15;25(16):5143-5155. PMID: PMC6697588
226. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, **Hamadani M**. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2019 Sep;25(9):1859-1868. PMID: PMC6755039
227. Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, **Hamadani M**, Weisdorf DJ, Chu H, Rashidi A. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. *Blood Adv*. 2019 Sep 10;3(17):2581-2585. PMID: PMC6737418
228. Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, **Hamadani M**, Usmani S, Ford P. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. *Biol Blood Marrow Transplant*. 2019 Oct;25(10):e305-e309.
229. Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, **Hamadani M**, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. *Blood Adv*. 2019 Oct 08;3(19):2836-2844. PMID: PMC6784523
230. Guru Murthy GS, Szabo A, **Hamadani M**, Fenske TS, Shah NN. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. *Oncologist*. 2019 Nov;24(11):1488-1495. PMID: PMC6853108

231. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, **Hamadani M**, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019 Dec;25(12):2305-2321.
232. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, **Hamadani M**, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. *Biol Blood Marrow Transplant*. 2019 Dec;25(12):2330-2337.
233. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, **Hamadani M**, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. *Amyloid*. 2019 Dec;26(4):210-215.
234. Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, **Hamadani M**, Hari P, D'Souza A. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. *J Clin Apher*. 2019 Dec;34(6):686-691. PMID: PMC6957224
235. Kahl BS, **Hamadani M**, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardesna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. *Clin Cancer Res*. 2019 Dec 01;25(23):6986-6994.
236. Epperla N, **Hamadani M**, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. *Cancer*. 2019 Dec 15;125(24):4417-4425.
237. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, **Hamadani M**. Allogeneic transplantation in elderly patients >65 years with non-Hodgkin lymphoma: a time-trend analysis. *Blood Cancer J*. 2019 Dec 03;9(12):97. PMID: PMC6890709
238. Abedin S, **Hamadani M**. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. *J Exp Pharmacol*. 2020;12:549-557. PMID: PMC7705269
239. Pidala J, **Hamadani M**, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. *Blood*. 2020 Jan 09;135(2):97-107. PMID: PMC6952830
240. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, **Hamadani M**, Fenske TS. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. *Blood Adv*. 2020 Jan 14;4(1):47-54. PMID: PMC6960457
241. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, **Hamadani M**, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. *Blood Adv*. 2020 Feb 11;4(3):467-476. PMID: PMC7013267
242. Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, **Hamadani M**, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas

- M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. *Hematol Oncol Stem Cell Ther.* 2020 Mar;13(1):7-16.
243. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, **Hamadani M**, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. *Biol Blood Marrow Transplant.* 2020 Mar;26(3):472-479. PMID: PMC7358778
244. Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, **Hamadani M**, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? *Biol Blood Marrow Transplant.* 2020 Apr;26(4):e77-e85. PMID: PMC7207150
245. Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralto S, **Hamadani M**, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. *J Clin Oncol.* 2020 Apr 20;38(12):1273-1283. PMID: PMC7164487
246. Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, **Hamadani M**. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. *Leuk Lymphoma.* 2020 Apr;61(4):869-874.
247. Kanate AS, Perales MA, **Hamadani M**. Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. *J Natl Compr Canc Netw.* 2020 May;18(5):635-643.
248. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, **Hamadani M**, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. *Biol Blood Marrow Transplant.* 2020 May;26(5):893-901.
249. Abedin SM, **Hamadani M**. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. *Expert Opin Investig Drugs.* 2020 May;29(5):423-427.
250. Fatobene G, Rocha V, St Martin A, **Hamadani M**, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleta JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. *J Clin Oncol.* 2020 May 10;38(14):1518-1526. PMID: PMC7213591
251. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, **Hamadani M**. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. *Cancer.* 2020 May 15;126(10):2279-2287. PMID: PMC7190439
252. Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, Pasquini MC, Weisdorf DJ, **Hamadani M**. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. *Biol Blood Marrow Transplant.* 2020 Jun;26(6):e138-e141.
253. **Hamadani M**, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. *Biol Blood Marrow*

- Transplant. 2020 Jun;26(6):1099-1105. PMID: PMC7255948
254. Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, **Hamadani M**, Chhabra S, Janz S, D'Souza A, Hari PN. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. *Cancer*. 2020 Jun 15;126(12):2791-2801.
255. Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, **Hamadani M**, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. *Biol Blood Marrow Transplant*. 2020 Jul;26(7):1288-1297.
256. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, **Hamadani M**, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. *Biol Blood Marrow Transplant*. 2020 Jul;26(7):e161-e166. PMID: PMC7206419
257. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, **Hamadani M**. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020 Jul;26(7):1247-1256.
258. **Hamadani M**, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. *Biol Blood Marrow Transplant*. 2020 Jul;26(7):1312-1317. PMID: PMC7194895
259. Badar T, Astle J, Kakar IK, Zellner K, Hari PN, **Hamadani M**. Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. *Br J Haematol*. 2020 Jul;190(2):e98-e101.
260. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, **Hamadani M**. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. *JAMA Oncol*. 2020 Jul 01;6(7):1011-1018. PMID: PMC7273311
261. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, **Hamadani M**, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. *Blood Adv*. 2020 Jul 14;4(13):3180-3190. PMID: PMC7362362
262. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, **Hamadani M**, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. *Biol Blood Marrow Transplant*. 2020 Aug;26(8):e177-e182. PMID: PMC7404814
263. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, **Hamadani M**, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange in multiple myeloma. *J Clin Apher*. 2020 Aug;35(4):307-315.
264. Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, **Hamadani M**. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. *Br J Haematol*. 2020 Aug;190(4):573-582. PMID: PMC7575614
265. Thapa B, Caimi PF, Ardeshtna KM, Solh M, Carlo-Stella C, Kahl BS, **Hamadani M**. CD19 antibody-drug

- conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. *Blood Adv.* 2020 Aug 25;4(16):3850-3852. PMID: PMC7448593
266. Abid MB, **Hamadani M**, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. *Biol Blood Marrow Transplant.* 2020 Sep;26(9):1670-1678.
267. Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, **Hamadani M**, Fenske TS, Dropuli? B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. *Nat Med.* 2020 Oct;26(10):1569-1575.
268. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, **Hamadani M**. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1876-1885. PMID: PMC7571859
269. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, **Hamadani M**. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. *Biol Blood Marrow Transplant.* 2020 Nov;26(11):2011-2017.
270. Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, **Hamadani M**, Hari PN, Chhabra S. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):2229-2236.
271. **Hamadani M**, Litovich C, Ahn KW. Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply. *JAMA Oncol.* 2020 Dec 01;6(12):1984.
272. Alghwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, **Hamadani M**, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):2181-2189. PMID: PMC7380217
273. Bal S, Costa LJ, Sauter C, Litovich C, **Hamadani M**. Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. *Transplant Cell Ther.* 2021 Jan;27(1):55.e1-55.e7. PMID: PMC7965782
274. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, **Hamadani M**. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. *Transplant Cell Ther.* 2021 Jan;27(1):58-66. PMID: PMC7972998
275. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, **Hamadani M**, Carpenter PA, Nagler A. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2021 Jan;27(1):6-20.
276. Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, **Hamadani M**, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS. Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. *JCO Precis Oncol.* 2021;5. PMID: PMC8140814
277. Dhakal B, Hari PN, Usmani SZ, **Hamadani M**. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. *Bone Marrow Transplant.* 2021 Jan;56(1):9-19.
278. Epperla N, **Hamadani M**. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. *Curr Hematol*

- Malig Rep. 2021 Feb;16(1):19-24.
279. Shah NN, **Hamadani M**. Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? *J Clin Oncol*. 2021 Feb 10;39(5):487-498.
280. Alotaibi S, **Hamadani M**, Al-Mansour M, Aljurf M. Breast Implant-associated Anaplastic Large Cell Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2021 Mar;21(3):e272-e276.
281. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, **Hamadani M**. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. *Hematol Oncol Stem Cell Ther*. 2021 Mar;14(1):65-70. PMID: PMC7543702
282. Badar T, Johnson BD, **Hamadani M**. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. *Bone Marrow Transplant*. 2021 Mar;56(3):683-685.
283. Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, **Hamadani M**. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? *Blood*. 2021 Mar 11;137(10):1416-1423. PMID: PMC7955408
284. Al Somali Z, **Hamadani M**, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M. Enteropathy-Associated T cell Lymphoma. *Curr Hematol Malig Rep*. 2021 Apr;16(2):140-147.
285. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, **Hamadani M**, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ. Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. *Bone Marrow Transplant*. 2021 Apr;56(4):786-797. PMID: PMC8168056
286. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, **Hamadani M**. Correction: Allogeneic transplantation in elderly patients >65 years with non-Hodgkin lymphoma: a time-trend analysis. *Blood Cancer J*. 2021 Apr 29;11(4):82. PMID: PMC8085088
287. Yassine F, Sandoval-Sus J, Ayala E, Chavez J, **Hamadani M**, Kharfan-Dabaja MA. Cellular Therapies for Mantle Cell Lymphoma. *Transplant Cell Ther*. 2021 May;27(5):363-370.
288. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, **Hamadani M**, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ. Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. *Transplant Cell Ther*. 2021 May;27(5):380-388. PMID: PMC8415092
289. **Hamadani M**, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardesna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. *Blood*. 2021 May 13;137(19):2634-2645. PMID: PMC8138546
290. **Hamadani M**, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. *Lancet Haematol*. 2021 Jun;8(6):e433-e445. PMID: PMC9241579
291. Caimi PF, Ai W, Alderuccio JP, Ardesna KM, **Hamadani M**, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2021 Jun;22(6):790-800.
292. Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, **Hamadani M**, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. *Transplant Cell Ther*. 2021 Jun;27(6):483.e1-483.e6. PMID: PMC8217373
293. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, **Hamadani M**, Labopin

- M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ. Correction: Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. *Bone Marrow Transplant.* 2021 Jun;56(6):1486.
294. Jella TK, Cwalina TB, Treisman J, **Hamadani M**. Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. *Clin Lymphoma Myeloma Leuk.* 2021 Jul;21(7):e619-e625.
295. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, **Hamadani M**, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. *Leukemia.* 2021 Jul;35(7):2076-2085. PMID: PMC8257494
296. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, **Hamadani M**, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. *Leukemia.* 2021 Jul;35(7):2140. PMID: PMC8329698
297. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, **Hamadani M**, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. *JAMA Oncol.* 2021 Jul 01;7(7):993-1003. PMID: PMC8283558
298. Abboud R, Wan F, Mariotti J, Arango M, Castagna L, Romee R, **Hamadani M**, Chhabra S. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. *Bone Marrow Transplant.* 2021 Nov;56(11):2763-2770.
299. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Frint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, **Hamadani M**, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2021 Aug;27(8):642-649.
300. Munshi PN, **Hamadani M**, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. *Bone Marrow Transplant.* 2021 Dec;56(12):2911-2921. PMID: PMC8639670
301. Riedell PA, **Hamadani M**, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. *Transplant Cell Ther.* 2021 Nov;27(11):911.e1-911.e7. PMID: PMC8556305
302. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski

- S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, **Hamadani M**, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. *Leukemia*. 2021 Sep;35(9):2672-2683.
303. Munshi PN, **Hamadani M**, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. *Transplant Cell Ther*. 2021 Sep;27(9):720-728. PMID: PMC8447221
304. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, **Hamadani M**, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. *Eur J Haematol*. 2021 Sep;107(3):301-310. PMID: PMC8338766
305. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, **Hamadani M**. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. *Blood Adv*. 2021 Sep 28;5(18):3528-3539. PMID: PMC8945575
306. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, **Hamadani M**. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2021 Oct;21(10):e775-e781.
307. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledebner N, Hari P, **Hamadani M**. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. *Blood*. 2021 Oct 07;138(14):1278-1281. PMID: PMC8332674
308. Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, **Hamadani M**. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. *Br J Haematol*. 2021 Nov;195(3):429-432. PMID: PMC9293486
309. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, **Hamadani M**, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. *Am J Hematol*. 2021 Nov 01;96(11):1374-1384. PMID: PMC8511300
310. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, **Hamadani M**, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. *Am J Hematol*. 2021 Nov 01;96(11):1374-1384. PMID: PMC8511300
311. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, **Hamadani M**, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of

- practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. *Am J Hematol*. 2021 Nov 01;96(11):1374-1384. PMID: PMC8511300
312. Patel A, Murthy GSG, **Hamadani M**, Szabo A, Knight JM. The Impact of Beta-Blocker Use at the Time of Hematopoietic Cell Transplantation on the Development of Acute and Chronic Graft-Versus-Host Disease. *Hematol Oncol Stem Cell Ther*. 2023 Apr 04;16(3):209-216.
313. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, **Hamadani M**, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. *Transplant Cell Ther*. 2021 Nov;27(11):885-907. PMID: PMC8556300
314. Ahmed N, **Hamadani M**. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. *Expert Rev Anticancer Ther*. 2021 Dec;21(12):1313-1320.
315. Zurko J, **Hamadani M**. Loncastuximab tesirine for diffuse large B-cell lymphoma. *Drugs Today (Barc)*. 2021 Dec;57(12):733-743.
316. Epperla N, **Hamadani M**. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. *Hematology Am Soc Hematol Educ Program*. 2021 Dec 10;2021(1):247-253. PMID: PMC8791097
317. Riedell PA, **Hamadani M**, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. *Br J Haematol*. 2021 Dec;195(5):757-763. PMID: PMC8627449
318. Furqan F, **Hamadani M**. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. *Ther Adv Hematol*. 2022;13:20406207221087511. PMID: PMC8943462
319. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, **Hamadani M**, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. *Blood Adv*. 2021 Dec 14;5(23):5179-5189. PMID: PMC9153047
320. Ahmed G, **Hamadani M**, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. *Blood Adv*. 2021 Dec 28;5(24):5626-5630. PMID: PMC8714710
321. Iqbal M, Savani BN, **Hamadani M**. New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. *EJHaem*. 2022 Jan;3(Suppl 1):11-23. PMID: PMC8725814
322. **Hamadani M**, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. *Blood Adv*. 2022 Jan 25;6(2):486-494. PMID: PMC8791562
323. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, **Hamadani M**, Epperla N. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. *Hematol Oncol*. 2022 Feb;40(1):48-56.
324. Jella T, Cwalina TB, **Hamadani M**. Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients. *Clin Lymphoma Myeloma Leuk*. 2022 Feb;22(2):e128-e134.
325. Meyers G, **Hamadani M**, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE. Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. *Bone Marrow Transplant*. 2022 Feb;57(2):302-303. PMID: PMC8825705
326. **Hamadani M**, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. *Blood Adv*. 2022 Feb 08;6(3):920-930. PMID: PMC8945300
327. Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, **Hamadani M**, Dhakal B,

- Hari P, Rao S, Carlson K, Williams CL, Knight JM. Rap1A, Rap1B, and β -Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. *Yale J Biol Med.* 2022 Mar;95(1):45-56. PMID: PMC8961707
328. Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, **Hamadani M**. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. *Blood.* 2022 Mar 03;139(9):1330-1339. PMID: PMC8900276
329. Dhakal B, Chhabra S, Savani BN, **Hamadani M**. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. *Br J Haematol.* 2022 Apr;197(1):28-40.
330. Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, **Hamadani M**. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. *Br J Haematol.* 2022 Apr;197(2):212-222. PMID: PMC9018546
331. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, **Hamadani M**. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. *Cancer Cell.* 2022 Apr 11;40(4):340-342. PMID: PMC8864440
332. Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakhri RE, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge PW, Yakoub-Agha I, **Hamadani M**, Weisdorf D, Greinix H, Aljurf M. Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2022 Aug;28(8):455-462.
333. Derman BA, Belli AJ, Battiwalla M, **Hamadani M**, Kansagra A, Lazarus HM, Wang CK. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. *Blood Rev.* 2022 May;53:100913.
334. Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, **Hamadani M**, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. *JAMA Oncol.* 2022 May 01;8(5):773-775. PMID: PMC8914887
335. Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, **Hamadani M**. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. *Clin Lymphoma Myeloma Leuk.* 2022 May;22(5):e335-e339.
336. Calabretta E, **Hamadani M**, Zinzani PL, Caimi P, Carlo-Stella C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. *Blood.* 2022 Jul 28;140(4):303-308. PMID: PMC9335500
337. Mei M, **Hamadani M**, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF. Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. *Haematologica.* 2022 May 01;107(5):1214-1217. PMID: PMC9052914
338. Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, **Hamadani M**. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. *Transplant Cell Ther.* 2022 Aug;28(8):487.e1-487.e7. PMID: PMC9375438
339. AlYamany R, Kharfan-Dabaja MA, **Hamadani M**, Alshaibani A, Aljurf M. The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time. *Curr Oncol.* 2022 May 23;29(5):3759-3769. PMID: PMC9139652
340. **Hamadani M**, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. *Clin Lymphoma Myeloma Leuk.* 2022 Jun;22(6):373-381.
341. Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales MA, Carpenter PA, **Hamadani M**. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. *Transplant Cell Ther.* 2022 Sep;28(9):523-529.

342. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, **Hamadani M**, Usmani S, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. *Transplant Cell Ther.* 2022 Jun;28(6):284-293.
343. Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, **Hamadani M**, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. *Clin Lymphoma Myeloma Leuk.* 2022 Jul;22(7):e495-e497. PMID: PMC8767926
344. Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, **Hamadani M**, McGuirk J, Shune L. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. *Transplant Cell Ther.* 2022 Jul;28(7):358-364.
345. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, **Hamadani M**, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. *Transplant Cell Ther.* 2022 Jul;28(7):409.e1-409.e10. PMID: PMC9840526
346. **Hamadani M**. Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? *Haematologica.* 2022 Jul 01;107(7):1500-1502. PMID: PMC9244808
347. Halahleh K, Al Rimawi D, Abu Ghosh A, Muradi I, Da'na W, **Hamadani M**. The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia. *Hematol Oncol Stem Cell Ther.* 2022 Dec 23;15(4):219-222.
348. **Hamadani M**, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C. Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. *Clin Lymphoma Myeloma Leuk.* 2022 Aug;22(8):e738-e744.
349. Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, **Hamadani M**, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. *EClinicalMedicine.* 2023 May;59:101983. PMID: PMC10133891
350. Ahmed N, Mahmoudjafari Z, **Hamadani M**, Hashmi H. Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. *Transplant Cell Ther.* 2023 Jun;29(6):399-402.
351. Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, **Hamadani M**, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, Shaw BE. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. *Transplant Cell Ther.* 2023 Jun;29(6):346.e1-346.e10. PMID: PMC10239334
352. Frait E, Abdel-Azim H, Bhatt NS, Broglie L, Chattha A, Kohorst M, Ktena YP, Lee MA, Long S, Qayed M, Sharma A, Stefanski H, Vatsayan A, Wray L, **Hamadani M**, Carpenter PA. Evaluation of Children with Malignancies for Blood and Marrow Transplantation: A Report from the ASTCT Committee on Practice Guidelines. *Transplant Cell Ther.* 2023 May;29(5):293-301.
353. Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, **Hamadani M**. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. *Haematologica.* 2023 Aug 01;108(8):2249-2254. PMID: PMC10388259
354. Mussetti A, Kanate AS, Wang T, He M, **Hamadani M**, Finel H Sr, Boumendil A Sr, Glass B, Castagna L, Dominietto A, McGuirk J, Blaise D, Gülbas Z, Diez-Martin J, Marsh SGE, Paczesny S, Gadalla SM, Dreger P, Zhang MJ, Spellman SR, Lee SJ, Bolon YT, Sureda A. Haploidentical Versus Matched

- Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. *Transplant Cell Ther.* 2023 Mar;29(3):184.e1-184.e9. PMID: PMC10316698
355. Sasu BJ, Opitck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, **Hamadani M**, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. *Mol Ther.* 2023 Mar 01;31(3):676-685. PMID: PMC10014221
356. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, **Hamadani M**, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. *Blood Adv.* 2023 Jun 13;7(11):2287-2296. PMID: PMC10225877
357. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, **Hamadani M**, Carpenter P, DeZern AE. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. *Transplant Cell Ther.* 2023 Feb;29(2):71-81.
358. Furqan F, Maring M, Szabo A, Fenske TS, **Hamadani M**, Shah NN. Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. *Blood Adv.* 2023 Jun 13;7(11):2463-2467. PMID: PMC10241849
359. Kuruvilla J, Armand P, **Hamadani M**, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. *Leuk Lymphoma.* 2023 Jan;64(1):130-139.
360. Toukam M, Wuerthner J, Havenith K, **Hamadani M**, Caimi PF, Kopotsha T, Cruz HG, Boni JP. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. *Cancer Chemother Pharmacol.* 2023 Jan;91(1):13-24.
361. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, **Hamadani M**. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [*Biology of Blood and Marrow Transplantation* 26/10 (2020) 1876-1885]. *Transplant Cell Ther.* 2022 Oct;28(10):717.
362. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, **Hamadani M**, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [*Transplantation and Cellular Therapy* 26/8 (2020) e177-e182]. *Transplant Cell Ther.* 2022 Oct;28(10):715-716.
363. Furqan F, Ahn KW, Chen Y, Kaur M, Abutalib SA, Ahmed N, Ahmed S, Kharfan-Dabaja MA, Friedberg J, Gregory T, Hill L, Sterling C, Barta SK, Shadman M, Perales MA, Zain J, Herrera AF, Sauter C, **Hamadani M**. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. *Br J Haematol.* 2023 Jan;200(1):54-63. PMID: PMC9772096
364. Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, **Hamadani M**, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR. Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. *Haematologica.* 2023 Jan 01;108(1):250-256. PMID: PMC9827178
365. Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, **Hamadani M**, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. *Am J Hematol.* 2022 Dec;97(12):1580-1588.
366. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, **Hamadani M**. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. *Clin Lymphoma Myeloma Leuk.* 2022 Nov;22(11):863-868.
367. Toukam M, Boni JP, **Hamadani M**, Caimi PF, Cruz HG, Wuerthner J. Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-

- Hodgkin lymphoma. *Cancer Chemother Pharmacol.* 2023 Jan;91(1):1-12.
368. Epperla N, Reljic T, Chowdhury SM, Ferreri AJM, Kumar A, **Hamadani M**. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis. *Hematol Oncol.* 2023 Feb;41(1):88-96.
369. Muhsen IN, El Fakih R, **Hamadani M**, Lazarus HM, Kharfan-Dabaja MA, Aljurf M. Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas. *Clin Hematol Int.* 2022 Jun;4(1-2):1-10. PMID: PMC9358781
370. Sehgal A, Hoda D, Riedell PA, Ghosh N, **Hamadani M**, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. *Lancet Oncol.* 2022 Aug;23(8):1066-1077.
371. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, **Hamadani M**, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. *Haematologica.* 2023 Jan 01;108(1):98-109. PMID: PMC9827150
372. Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshtna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, **Hamadani M**, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. *Blood Adv.* 2022 Aug 23;6(16):4736-4739. PMID: PMC9631657
373. Perales MA, Anderson LD Jr, Jain T, Kenderian SS, Oluwole OO, Shah GL, Svoboda J, **Hamadani M**. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2022 Sep;28(9):546-559. PMID: PMC9427727
374. Meyers G, **Hamadani M**, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. *Bone Marrow Transplant.* 2023 Dec;58(12):1416-1418. PMID: PMC11732251
375. Gordon LI, Liu FF, Braverman J, Hoda D, Ghosh N, **Hamadani M**, Hildebrandt GC, Peng L, Guo S, Shi L, Sehgal A. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. *Haematologica.* 2024 Mar 01;109(3):857-866. PMID: PMC10905070
376. Caimi PF, Ai WZ, Alderuccio JP, Ardeshtna KM, **Hamadani M**, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. *Haematologica.* 2024 Apr 01;109(4):1184-1193. PMID: PMC10985439
377. Arshad S, Fang X, Ahn KW, Kaur M, Scordo M, Sauter CS, Furqan F, Awan FT, **Hamadani M**. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. *Bone Marrow Transplant.* 2023 Nov;58(11):1203-1208. PMID: PMC11078515
378. **Hamadani M**, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. *Hematol Oncol.* 2023 Dec;41(5):848-857.
379. Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, **Hamadani M**. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2023 Oct;29(10):594-597.
380. Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, **Hamadani M**. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies

- in Diffuse Large B Cell Lymphoma. *Transplant Cell Ther.* 2023 Sep;29(9):548-555.
381. Bolaños-Meade J, **Hamadani M**, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Goptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. *N Engl J Med.* 2023 Jun 22;388(25):2338-2348. PMID: PMC10575613
382. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, **Hamadani M**, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. *Br J Haematol.* 2024 Mar;204(3):887-891.
383. Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, **Hamadani M**, Hunink MGM, Cutler C. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis. *Ann Intern Med.* 2023 Dec;176(12):1625-1637.
384. Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD Jr, **Hamadani M**. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2024 Feb;30(2):131-142.
385. Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, **Hamadani M**, Westin JR, Bachanova V. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20⁺ B Cell Lymphoma. *Transplant Cell Ther.* 2024 Feb;30(2):241.e1-241.e8.
386. Alderuccio JP, Reis IM, **Hamadani M**, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshta KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial. *Clin Cancer Res.* 2024 Jan 05;30(1):139-149. PMID: PMC10872617
387. Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, **Hamadani M**, Szabo A, D'Souza A, N3C consortium. Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. *Bone Marrow Transplant.* 2024 Jan;59(1):121-124.
388. **Hamadani M**, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshta KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. *Blood Adv.* 2024 Jan 09;8(1):93-98. PMID: PMC10787240
389. El Warrak S, Kharfan-Dabaja MA, Iqbal M, **Hamadani M**, Chavez J, Mohty R. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. *Bone Marrow Transplant.* 2024 Feb;59(2):162-170.
390. Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, **Hamadani M**. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. *Transplant Cell Ther.* 2024 Mar;30(3):285-297.
391. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, **Hamadani M**. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2024 Mar;59(3):373-379.
392. Rezazadeh A, Pruett J, Detzner A, Edwin N, **Hamadani M**, Shah NN, Fenske TS. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. *Clin Lymphoma Myeloma Leuk.* 2024 Apr;24(4):254-259.
393. Karmali R, Galvez C, **Hamadani M**, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. *Blood Adv.* 2024 Apr 09;8(7):1612-1620. PMID: PMC10987893
394. Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV,

- Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, **Hamadani M**, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101). medRxiv. 2024 Jan 25. PMID: PMC10854344
395. Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarathi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, **Hamadani M**, D'Souza A, Schinke C. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. *Bone Marrow Transplant*. 2024 May;59(5):647-652.
396. Caimi PF, **Hamadani M**, Carlo-Stella C, Nickaen M, Jordie E, Utsey K, Knab T, Zammarchi F, Cucchi D, Pantano S, Havenith K, Wang Y, Boni J. In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. *EJHaem*. 2024 Feb;5(1):76-83. PMID: PMC10887233
397. Levis MJ, **Hamadani M**, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB, BMT-CTN 1506/MORPHO Study Investigators. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of *FLT3*. *J Clin Oncol*. 2024 May 20;42(15):1766-1775. PMID: PMC11095884
398. Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp Z, Dholaria B, Jain T, Perales MA, Carpenter PA, **Hamadani M**, Dhakal B, Usmani SZ. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy. *Transplant Cell Ther*. 2024 Aug;30(8):750-759.
399. Ahmed G, Alsouqi A, Szabo A, Samples L, Shadman M, Awan FT, Rojek AE, Riedell PA, Iqbal M, Fenske TS, Kharfan-Dabaja MA, Ito S, **Hamadani M**. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. *Blood Adv*. 2024 Jul 09;8(13):3528-3531. PMID: PMC11261102
400. Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, **Hamadani M**, Jimenez Jimenez A. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. *Leukemia*. 2024 Jul;38(7):1564-1569. PMID: PMC11271761
401. Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, Riedell PA, Awan F, Samples L, Shadman M, Hu M, Bachanova V, Wesson W, Ahmed N, Iqbal M, Kharfan-Dabaja MA, Scordo M, Johnson PC, Chen YB, Ito S, **Hamadani M**, Frigault M. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. *Am J Hematol*. 2024 Aug;99(8):1624-1627.
402. Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, **Hamadani M**, Herrera AF, Ahmed S. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. *Br J Haematol*. 2024 Sep;205(3):1202-1207. PMID: PMC11499028
403. Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, **Hamadani M**, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. *Clin Infect Dis*. 2024 Aug 16;79(2):542-554. PMID: PMC11327798
404. Ahmed G, Furqan F, Nasrollahi E, **Hamadani M**. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma. *Expert Rev Anticancer Ther*. 2024 Aug;24(8):705-715.
405. Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, **Hamadani M**, Anwer

- F, Hashmi H, Ahmed N. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. *Transplant Cell Ther.* 2024 Sep;30(9):876-884.
406. Furqan F, Bhatlapenumarthy V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, **Hamadani M**. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. *Blood Adv.* 2024 Aug 27;8(16):4320-4329. PMID: PMC11372811
407. Khaliq A, Wesson W, Logan E, Tabak C, Mushtaq MU, Lin T, Baranda J, Shune L, Abdallah AO, McGuirk J, **Hamadani M**, Ahmed N. The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma. *Clin Lymphoma Myeloma Leuk.* 2024 Oct;24(10):e344-e349.
408. Hansen DK, Dhakal B, **Hamadani M**, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okoroza P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma. *Front Immunol.* 2024;15:1405452. PMID: PMC11194690
409. Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, Akinola I, Phelan R, Broglie L, Auletta JJ, Steinert P, Bolon YT, Akhtar O, Bloomquist J, Chen M, Devine SM, Bupp C, **Hamadani M**, Hengen M, Jaglowski S, Kaur M, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Rizzo D, Saber W, Spellman SR, Stefanski HE, Tuschl E, Yusuf R, Zhan K, Flynn KE, Shaw BE. Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry. *Transplant Cell Ther.* 2024 Sep;30(9):917.e1-917.e12. PMID: PMC11587342
410. Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, **Hamadani M**, Kharfan-Dabaja MA. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. *Transplant Cell Ther.* 2024 Sep;30(9):832-843.
411. Kim NH, **Hamadani M**, Abedin S. New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature. *Expert Opin Investig Drugs.* 2024 Aug;33(8):791-799. PMID: PMC11305901
412. Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, **Hamadani M**. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. *Blood Cancer J.* 2024 Jul 08;14(1):108. PMID: PMC11231252
413. Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter LG, Sauter C, **Hamadani M**, Herrera A, Shouval R, Shadman M. CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma. *Blood Adv.* 2024 Oct 22;8(20):5290-5296. PMID: PMC11497379
414. Levis MJ, **Hamadani M**, Horowitz MM, Chen YB, BMT CTN 1506 Investigators. Reply to S. Fuji. *J Clin Oncol.* 2024 Nov 10;42(32):3881-3882. PMID: PMC11540746
415. Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, **Hamadani M**. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. *Transplant Cell Ther.* 2024 Dec;30(12):1191.e1-1191.e8.
416. Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, **Hamadani M**, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL, AGAVE-201 Investigators. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. *N Engl J Med.* 2024 Sep 19;391(11):1002-1014.
417. Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Geethakumari PR, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, **Hamadani M**, Herrera AF, Lee CJ. Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy. *Haematologica.* 2025 Jan 01;110(1):218-221. PMID: PMC11694114

418. Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, **Hamadani M**, Freeman CL, Akhtar OS. Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. *Br J Haematol*. 2024 Dec;205(6):2370-2375.

Books, Chapters, and Reviews

1. **Hamadani M**, Devine SM Patient evaluation before transplantation (adult). In: Wingard JR, Gastineau D, Leather H, Snyder EL, Szczepiorkowski ZM, eds. *Hematopoietic Stem cell transplantation: a handbook for clinicians*, 1st ed. Bethesda, MD AABB. 2009 Sept; 27-43
2. **Hamadani M**, Jaffe ES. Hodgkin lymphoma. In: Abraham J, Gulle JL, Allegra CJ, eds. *The Bethesda Handbook of Clinical Oncology*, 4th ed. Philadelphia, PA Lippincott Williams & Wilkins. 2014 March; 374-384
3. Lazarus HM, **Hamadani M**, Hari PN. Autologous hematopoietic cell transplantation. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*, 10th ed. Philadelphia, PA Lippincott Williams & Wilkins. 2014 Dec; 1907-1916
4. Hsu J, **Hamadani M**, Devine SM. Patient evaluation before transplantation (adult). In: Wingard JR, Gastineau D, Leather H, Snyder EL, Szczepiorkowski ZM, eds. *Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians*, 2nd ed. Bethesda, MD AABB. 2015 Jan; 43-58
5. Saber W, **Hamadani M**, Hashmi S, Hari P. Lymphoma: working committee and data reporting after transplantation in lymphoma. In: Savani BN, Mohty M, eds. *Clinical Guide to Transplantation in Lymphoma*, 1st ed. Hoboken, NJ Wiley-Blackwell. 2015 Aug; 13-22
6. Kharfan-Dabaja MA, El-Jurdi N, **Hamadani M**, Ayala E. Preparative regimens for lymphoma: allogeneic hematopoietic stem cell transplantation. In: Savani BN, Mohty M, eds. *Clinical Guide to Transplantation in Lymphoma*, 1st ed. Hoboken, NJ Wiley-Blackwell; 2015 Aug; 57-68
7. Veltri L, Savani BN, Kharfan-Dabaja MA, **Hamadani M**, Kanate AS. Diffuse large B-cell lymphoma. In: Savani BN, Mohty M, eds. *Clinical Guide to Transplantation in Lymphoma*, 1st ed. Hoboken, NJ Wiley-Blackwell. 2015 Aug; 145-160
8. Epperla N, Hashami H, **Hamadani M**: "Hematopoietic cell transplantation in indolent non-Hodgkin lymphomas." In: Abutalib SA., Hari P., eds. *Clinical Manual of Blood and Bone Marrow Transplantation*, 1st ed. Hoboken, NJ: Wiley-Blackwell; 2017: 140-150.
9. **Hamadani M**, Hari PN: "Indications and outcomes of allogeneic hematopoietic cell transplantation for hematologic malignancies in adults" In: Hoffman R., Benz EJ Jr., Silberstein LE., Heslop H., Weitz J., Anastasi J., Abutalib SA., eds. *Hematology: Basic Principles and Practice*, 7th ed. Philadelphia, PA: Elsevier; 2017: 1596-1607.
10. Epperla N, **Hamadani M**, Horowitz MM: "Indications for allogeneic hematopoietic cell transplantation in adults." In: Gluckman E., Niederwieser D., Aljurf M., eds. *Establishing a Hematopoietic Stem Cell Transplantation Unit*, 1st ed. Cham, Switzerland: Springer International Publishing AG. 2018: 83-110.
11. Lazarus HM, **Hamadani M**, Hari PN: "Autologous hematopoietic cell transplantation." In: DeVita VT., Lawrence TS., Rosenberg SA., eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*, 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2019: 2008-2019.
12. Guru Murthy GS, **Hamadani M**, Hari PN. "Haploidentical hematopoietic cell transplantation in lymphomas." In: Ciurea SO., Handgretinger R, eds. *Haploidentical Transplantation: Concepts and Clinical Application*, 1st ed. Cham, Switzerland: Springer International Publishing AG. 2018:245-260.
13. Kanate AS, Craig M, **Hamadani M**. "Hematopoietic cell transplantation." In: Abraham J., Gulle JL., Allegra CJ., eds. *The Bethesda Handbook of Clinical Oncology*, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2019: 404-416.

Non-Refereed Journal Publications/Original Papers

1. Hamadani SM, Chaudhary L. Limitations of Sokal score in patients with chronic myeloid leukemia. *J Coll Physicians Surg Pak*. 2007 Mar;17(3):182; author reply 182.
2. **Hamadani M**, Kraut EH. Review: isolated skeletal involvement in hairy cell leukemia. *Clin Adv Hematol Oncol*. 2008 Apr;6(4):294-6.
3. **Hamadani M**, Blum W Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. *Clinical Leukemia*. 2009 February; 3(1):47-57
4. **Hamadani M**, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. *Cancer Control*. 2011 Oct;18(4):237-45.
5. Chaudhary L, **Hamadani M**. Management strategies for follicular lymphoma patients in remission after

- modern frontline chemoimmunotherapies. *J Blood Disorders Transf.* 2013 January; 4(1):1000e105
6. **Hamadani M.** Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? *Bone Marrow Transplant.* 2013 Aug;48(8):1013-21.
 7. **Hamadani M,** Kanate AS Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. *Community Oncology.* 2013 October;10(10):279-281
 8. **Hamadani M,** Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. *Semin Hematol.* 2014 Jan;51(1):73-86.
 9. **Hamadani M.** Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplant? *Biol Blood Marrow Transplant.* 2014 Mar;20(3):292-4.
 10. Kanate AS, Pasquini MC, Hari PN, **Hamadani M.** Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. *World J Stem Cells.* 2014 Apr 26;6(2):69-81. PMID: PMC3999783
 11. Epperla N, Fenske TS, Hari PN, **Hamadani M.** Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. *World J Transplant.* 2015 Sep 24;5(3):81-8. PMID: PMC4580930
 12. Epperla N, **Hamadani M.** "Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances." *Hematol Oncol Stem Cell Ther.* 2017 December;10(4):277-284.
 13. **Hamadani M,** Horowitz MH. "Allogeneic transplantation for follicular lymphoma: Does one size fit all?" *J Oncol Pract.* 2017 Dec; 13(12):798-806.
 14. **Hamadani M.** "Advances in transplantation for lymphomas resulting from CIBMTR Lymphoma Working Committee's research portfolio: A five-year report (2013-2018)." *Advances in Cell and Gene Therapy.* 2018 Nov;1(3):e17-e21.
 15. Hashmi H, **Hamadani M,** Awan FT. "Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma." *Expert Opin Pharmacother.* 2018 Oct;19(15):1631-1634.

Abstracts

1. Mosallaei-Benjamin M, **Hamadani M,** Scofield H, Holla P, Selby G. The effects of hyperglycemia on hematopoietic stem cell transplantation. Poster Presentation: 39th Annual Meeting of the American Society of Hematology 1997, San Diego, CA.
2. Sethi S, **Hamadani M,** Kamble R, Kharfan-Dabaja M, Selby G, Ozer H. Pure red cell aplasia (PRCA) following ABO-incompatible allogeneic bone marrow transplantation. Poster Presentation: BMT Tandem Meetings 2005, Keystone, CO.
3. **Hamadani M,** Kamble R, Sethi S, Kharfan-Dabaja M, Kern W, Ozer H, Selby G. Elevated mean corpuscular volume (MCV) following autologous hematopoietic stem cell transplantation: incidence and significance. Poster Presentation: BMT Tandem Meetings 2005, Keystone, CO.
4. **Hamadani M,** Tfayli A, Kojouri K, Awab A. Comparison of ondansetron, granisetron, and dolasetron with dexamethasone in the prevention of acute nausea and vomiting associated with platinum-based therapy. Poster Presentation: ASCO 2005, Orlando, FL.
5. **Hamadani M,** Padmanabhan R, Chaudhary L, Tfayli A. Relative efficacy of various 5- hydroxytryptamine receptor antagonists in the prevention and control of acute nausea and vomiting associated with platinum-based chemotherapy. Poster Presentation: ASCO 2006, Atlanta, GA.
6. **Hamadani M,** Awan F, Elder P, Porcu P, Lin T, Blum K, Scholl D, Devine SM. Allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma: evidence of graft-versus-lymphoma effect. Poster Presentation: ASH 2007, Atlanta, GA.
7. **Hamadani M,** Hade EM, Elder P, Benson DM, Hofmeister CC. The effect of statin use at the time of autologous transplant on response and survival in patients with multiple myeloma. ASH 2007, Atlanta, GA.
8. **Hamadani M,** Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic R, Devine SM. High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG. ASH 2007, Atlanta, GA.
9. **Hamadani M,** Phillips G, Elder P, Jansak B, Blum W, Penza S, Lin TS, Farag SS, Devine SM. Phase-II study of infliximab for the prophylaxis of acute graft-versus-host disease (GVHD) Following allogeneic hematopoietic stem cell transplantation (AHSCT). Poster Presentation: BMT Tandem Meetings 2008,

San Diego, CA.

10. **Hamadani M**, Awan FT, Elder P, Lin TS, Andritsos L, Blum W, Blum KA, Devine SM. Rapid engraftment and low rates of graft-versus-host disease (GVHD) following reduced intensity conditioning (RIC) with fludarabine/busulfan/ATG (FBA) and Stem cell transplantation (SCT) using unrelated donors (URD). Poster Presentation: BMT Tandem Meetings 2008, San Diego, CA.
11. **Hamadani M**, Awan FT, Elder P, Devine SM. Statins reduce acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Poster Presentation: ASCO 2008, Chicago, IL.
12. Awan FT, **Hamadani M**, Lin TS, Porcu P, Blum KA, Benson DM Jr, Devine SM. Comparison of allogeneic vs. autologous transplantation for follicular lymphoma after transformation into diffuse large B-cell lymphoma. Poster Presentation: ASCO 2008, Chicago, IL.
13. **Hamadani M**, Blum KA, Elder P, Lin TS, Porcu P, Hofmeister CC, Blum W, Marcucci G, Benson D, Devine S. Allogeneic stem cell transplantation for patients with chemo-refractory or progressive aggressive non-Hodgkin's lymphomas. Poster Presentation: ASH 2008, San Francisco, CA.
14. **Hamadani M**, Blum W, Benson D, Blum KA, Porcu P, Elder P, Krugh D, Bechtel T, Andritsos L, Garzon R, Penza S, Lin TS, Devine S. Assessment of rabbit antithymocyte globulin (rATG) dose-intensity in patients with hematological malignancies undergoing allogeneic stem cell transplantation (ASCT) following reduced intensity conditioning (RIC) with fludarabine, busulfan and rATG (FBA). ASH 2008, San Francisco, CA.
15. Benson D, Andritsos L, **Hamadani M**, Lin T, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd J, Devine S. Natural killer cell immune reconstitution predicts outcomes for patients with chronic lymphocytic leukemia undergoing allogeneic stem cell transplantation. Poster Presentation: ASH 2008, San Francisco, CA.
16. Ferreri AJM, Govi S, Dognini GP, Bouzani M, Bollinguer RC, D'Incan M, Delaporte E, **Hamadani M**, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Crocchiolo R, Zucca E, Cavalli F, Ponzoni M. A cumulative series from 14 western countries suggests that rituximab significantly changed the dismal natural history of intravascular large B-cell lymphoma (IVL). Poster Presentation: ASH 2008, San Francisco, CA.
17. Andritsos L, **Hamadani M**, Heerema NA, Benson D, Hofmeister CC, Blum W, Flynn J, Jones JA, Elder P, Lin TS, Lozanski G, Byrd JC, Devine S. Attainment of minimal residual disease negative state is crucial for successful outcome of reduced intensity conditioning allogeneic stem cell transplantation in advanced chronic lymphocytic leukemia (CLL). Poster Presentation: ASH 2008, San Francisco, CA.
18. Pant S, **Hamadani M**, Crilley P, Szer J, Dodds AJ, Stevenson DE, Phillips G, Elder P, Nivison-Smith I, Avalos B, Penza P, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan E. Incidence of late failure following myeloablative conditioning with BuCy2 and matched sibling allogeneic stem cell transplantation for acute myeloid leukemia. Poster Presentation: ASH 2008, San Francisco, CA.
19. **Hamadani M**, Benson DM, Porcu P, Elder P, Andritsos L, Hofmeister CC, Krugh D, Garzon R, Lin T, Marcucci G, Blum W, Devine SM. Evaluation of rabbit antithymocyte globulin (rATG) dose-intensity in patients undergoing allogeneic stem cell transplantation (ASCT) following reduced intensity conditioning (RIC) with fludarabine, busulfan and rATG (FBA). Oral Presentation: BMT Tandem Meetings 2009, Tampa, FL.
20. **Hamadani M**, Baiocchi R, Lin T, Blum KA, Ezzone S, Benson DM, Devine SM. Feasibility of allogeneic peripheral blood stem cell transplantation (Allo-SCT) following reduced intensity conditioning (RIC) in HIV+ patients with hematological malignancies. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.
21. Benson DM, Hofmeister CC, **Hamadani M**, Panzner K, Smith MK, Penza SL, Elder P, Krugh D, O'Donnell L, Devine SM. Pre-mobilization bone marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide based induction regimens. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.
22. Grauer A, **Hamadani M**, Blum KA, Porcu P, Benson DM, Devine SM. Allogeneic versus autologous stem cell transplantation (SCT) for follicular lymphoma (FL). The James comprehensive cancer center experience. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.
23. **Hamadani M**, Liu K, Anthony BA, Gaughan A, Wang JJ, Shana'ah A, Byrd JC, Devine SM, Johnson AJ, Hadley GA. CD103 deficiency separates graft-versus-host disease and graft-versus-leukemia effects mediated by donor CD8T Cells. Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.
24. **Hamadani M**, Craig M, Abraham J, Tse W, Cumpston A, Stotler CJ, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. Evaluation Of busulfan's dose-intensity in patients undergoing allogeneic stem cell transplantation (ASCT) with two

- different fludarabine/busulfan/ATG (FBA)-based reduced intensity conditioning (RIC) regimens.
Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.
25. Jaglowski SM, Heerema N, Elder P, Scholl D, **Hamadani M**, Byrd JC, Devine S, Andritsos LA. Complex karyotype predicts poor response to salvage therapy and ineligibility for reduced intensity conditioning transplantation in CLL . Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.
 26. Osman S, Kanate AS, Bunner P, Leadmon S, Tse W, Cumpston A, Gibson L, Remick S, Abraham J, Craig M, **Hamadani M**. Response to induction chemotherapy with novel agents does not predict outcomes of multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Poster Presentation: ASH 2010, Orlando, FL.
 27. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon L, Bunner P, Watkins W, Gibson L, Tse W, Abraham J, Remick S, Craig M, **Hamadani M**. Higher infused CD34+ cell dose improves survival in patients undergoing in-vivo T-cell depleted, but not T-cell replete peripheral blood hematopoietic cell transplant. Poster Presentation: ASH 2010, Orlando, FL.
 28. Awan F, Osman S, Kochuparambil ST, Remick S, Abraham J, Craig M, Jillella AP, **Hamadani M**. Impact of response to thalidomide, lenalidomide or bortezomib containing induction chemotherapy on outcomes of multiple myeloma patients undergoing autologous transplantation - A multicenter analysis. Poster Presentation: ASH 2010, Orlando, FL.
 29. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon L, Bunner P, Watkins W, Gibson L, Tse W, Abraham J, Remick S, Craig M, **Hamadani M**. In-vivo T-cell depletion does not improve rates of graft-versus-host disease and transplantation outcomes in patients undergoing peripheral blood hematopoietic cell transplant. ASH 2010, Orlando, FL.
 30. Stauffer N, **Hamadani M**, Heaphy C, Santhanam R, Sandhu S, Costinean S, Nuovo J, Perrotti D, Croce CM, Hadley G, Marcucci G, Devine SM, Garzon R. Regulation of acute graft-versus-host disease by microRNA-155. Oral Presentation: ASH 2010, Orlando, FL.
 31. **Hamadani M**, Craig M, Abraham J, Tse W, Cumpston A, Gibson LF, Remick SC, Leadmon S, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic hematopoietic cell transplantation following fludarabine/busulfan/ATG-based reduced toxicity conditioning. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.
 32. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon S, Bunner P, Gibson L, Tse W, Abraham J, Remick S, Craig M, **Hamadani M**. In vivo T-cell depletion does not improve rates of graft-versus-host disease and transplantation outcomes in patients undergoing peripheral blood allogeneic hematopoietic cell transplant. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.
 33. Osman S, Kanate A, Bunner P, Leadmon S, Hart K, Goff L, Tse W, Cumpston A, Remick S, Abraham M, Craig M, **Hamadani M**. Cyclophosphamide/G-CSF cannot completely overcome Imid-induced impairment of peripheral blood stem cell mobilization in patients with multiple myeloma. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.
 34. Kanate AS, Chaudhary L, Cumpston A, Leadmon S, Bunner P, Bulian D, Gibson L, Tse W, Abraham J, Remick S, Craig M, **Hamadani M**. High rates of non-relapse mortality and graft-versus-host disease in patient undergoing allogeneic stem cell transplantation following non-myeloablative conditioning with TLI/ATG. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.
 35. Anthony B, **Hamadani M**, Wang JJ, Gaughan A, Hadley GA. CD103 blockade reduces CD8 T cell accumulation during GVHD, but does not attenuate GVL effects. Poster Presentation: AAI 2011, San Francisco, CA.
 36. Covey T, Gulrajani M, Hawtin R, Gayko U, Cumpston A, Craig M, **Hamadani M**, Rishel A, Park J, Abraham J, Remick S, Tse W. Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology. Poster Presentation: AACR-NCI-EORTC International Conference 2011, San Francisco, CA.
 37. **Hamadani M**, Kochuparambil TS, Osman S, Speir E, Craig M, Deremer D, Cumpston A, Morrison DD, Leadmon S, Sterling K, Bunner P, Sterrett M, Kota V, Jillella AP, Awan FT. Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies - A Multicenter Analysis. Oral Presentation: ASH 2011, San Diego, CA.
 38. Kharfan-Dabaja M, **Hamadani M**, Reljic T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous-autologous versus tandem autologous-reduced intensity allogeneic haematopoietic cell transplantation in multiple myeloma: results of a systematic review and meta-analysis. Oral Presentation: BMT Tandem Meetings 2012, San Diego, CA.

39. Forero A, **Hamadani M**, Goswami T, Sonet A, Verhoef G, Fanale MA, Bello CM, Huang W, Cheson BD. Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. Poster Presentation: ASCO 2012, Chicago, IL.
40. Richardson P, Berdeja J, Niesvizky R, Lonial S, Vesole D, **Hamadani M**, Chari A, Hari P, Htut M, Roy V, Stewart K, Berg D, Lin L, Gupta N, Di Bacco A, Hui A-M, Kumar S. MLN9708, an investigational proteasome inhibitor, combine with lenalidomide and dexamethasone in previously untreated multiple myeloma patients: Evaluation of weekly and twice-weekly dosing regimens. Oral Presentation: 17th Congress of the EHA 2012, Amsterdam, NL.
41. Kumar S, Berdeja J, Niesvizky R, Lonial S, **Hamadani M**, Stewart A, Roy V, Hari P, Vescio R, Berg D, Lin J, Bacco A, Gupta N, Hui Ai, Richardson P. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma. Oral Presentation: ASH 2012, Atlanta, GA.
42. Lust J, Usmani S, **Hamadani M**, Barranco C, Lacy M, Dispenzieri A, Gertz M, Dingli D, Russell S, Buadi F, Zeldenrust S, Hayman S, Rajkumar S, Kumar S, Thompson J, Taylor C, Dondero R. Phase 1b/2a dose-escalation study to evaluate the safety and tolerability of SNS01-T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. Poster Presentation: ASH 2012, Atlanta, GA.
43. Forero A, **Hamadani M**, Fanale M, Bello C, Kipps T, Offner F, Verhoef G, Federico M, Gregory S, Sonet A, Assouline S, Oteyza J, Tomas J, Cuneo A, Zhang W, Goswami T, Ibrahim R, Yao Z, Herbst R, Cheson B. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: results from a phase 1/2 study. Poster Presentation: ASH 2012, Atlanta, GA.
44. **Hamadani M**, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston C, Bunner P, Basu B, Tse W, Hennelly C, Vasu S, Klisovic R, Blum W, Jaglowski S, Benson, D, Andritsos L, Penza S, Hofmeister C, Geyer S, Devine S, Efebera Y. Immunomodulation of both donors and recipients with atorvastatin as a strategy for the prevention of acute graft-versus-host disease: results of two parallel prospective trials in recipients of matched sibling allogeneic hematopoietic cell Transplantation. Poster Presentation: ASH 2012, Atlanta, GA.
45. **Hamadani M**, Saber W, Carreras J, Ahn K, Laport G, Montoto S, Maloney D, Lazarus M. Impact of conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation for refractory grade-III follicular and diffuse large B-cell lymphomas: A CIBMTR Analysis. Oral Presentation: ASH 2012, Atlanta, GA.
46. **Hamadani M**, Saber W, Carreras J, Ahn K, Laport G, Montoto S, Maloney D, Lazarus M. Effect of graft source and transplant conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation for refractory mantle cell lymphoma: A CIBMTR Analysis. Oral Presentation: ASH 2012, Atlanta, GA.
47. Awan F, Kochuparambil S, Craig M, Cumpston A, Leadmon S, DeRemer D, Watkins K, Pantin J, Kota V, Jillella A, **Hamadani M**. A multicenter analysis of intermediate-dose cyclophosphamide versus plerixafor and granulocyte-colony stimulating factor for PB progenitor cell mobilization in patients with multiple myeloma treated with novel induction chemotherapies. Poster Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.
48. Veltri L, Regier M, Kanate A, Cumpston A, Leadmon S, Abraham J, Craig M, **Hamadani M**. Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplantation after non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin. Poster Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.
49. **Hamadani M**, Gibson L, Remick S, Petros W, Abraham J, Basu S, Tse W, Cumpston A, Bunner P, Craig M. Prospective evaluation of a 'two-pronged' strategy of atorvastatin administration as acute graft-versus-host disease prophylaxis, to both donors and recipients of matched related donor allogeneic hematopoietic cell transplantation. Oral Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.
50. Kharfan-Dabaja M, Nishihori T, Reljic T, Vazquez-Otero C, Baz R, **Hamadani M**, Ochoa-Bayona J, Alsina M, Djulbegovic B, Kumar A. Comparing efficacy of double- versus triple-combination therapy in newly diagnosed, transplant-eligible, patients with multiple myeloma: results of a metaanalysis. Poster Presentation: EBMT 2013, London, UK.
51. Chaudhary L, Awan F, Cumpston A, Tse W, Craig M, **Hamadani M**. Efficacy and cost of peripheral blood stem cell mobilization with low-dose cyclophosphamide compared with plerixafor in multiple myeloma patients treated with novel induction therapies. Poster Presentation: ASCO 2013, Chicago,

- IL.
52. Cooper BW, Kindwall-Keller T, Lazarus H, **Hamadani M**, Tse W, Basu S, Craig M. Phase I study of midostaurin and azacitidine in relapsed and elderly AML. Poster Presentation: ASCO 2013, Chicago, IL.
 53. Truong QV, Shah N, Knestruck M, Curley B, Craig M, **Hamadani M**. Limited utility of surveillance imaging for detection of relapse in non-Hodgkin lymphoma. Poster Presentation: ASCO 2013, Chicago, IL.
 54. **Hamadani M**, Forero A, Kipps T, Fanale M, Cuneo A, Perez de Oteyza J, Gladstone D, Goswami T, Ibrahim R, Liang M, Eck S, Elgeiyoushi N, Herbst R, Cheson BD. MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab. Poster Presentation: ASCO 2013, Chicago, IL.
 55. Younes A, Radford J, Ansell S, Gallamini A, Kim W, Feldman T, **Hamadani M**, Chung J, Wang J, Huebner D, Connors JM. Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus doxorubicin, bleomycin, vinblastine, and dacarbazine as front-line treatment for advanced classical Hodgkin lymphoma. Poster Presentation: ASCO 2013, Chicago, IL.
 56. Richardson P, Berdeja J, Niesvizky R, Lonial S, **Hamadani M**, Stewart A, Hari P, Vesole D, Roy V, Berg D, Lin J, Hui A, Kumar S. Weekly oral investigational proteasome inhibitor MLN9708 plus lenalidomide-dexamethasone in elderly patients with previously untreated multiple myeloma: Subset analysis of a phase I/II study. Poster Presentation: 18th Congress of the EHA 2013, Stockholm, SE.
 57. Efebera Y, Ranganathan P, Yu X, Hofstetter J, Garman S, Gibson F, Petros W, Craig M, Fernandez-Cymering C, Volinia S, **Hamadani M**, Marcucci G, Devine S, Garzon R. Serum microRNA signature in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Poster Presentation: 18th Congress of the EHA 2013, Stockholm, SE.
 58. Brown J, **Hamadani M**, Arnason J, Karlin L, Hayslip J, Wagner-Johnston N, Cartron G, Ribrag V, Guibert S, Ganguly S, Ailawadhi S, Ruiz-Soto R, Kersten M. SAR245409 monotherapy in relapsed, refractory follicular lymphoma: preliminary results from the phase II ARD12130 study. Oral Presentation: ASH 2013, New Orleans, LA.
 59. Forero-Torres A, **Hamadani M**, Fanale M, Bello C, Kipps T, Offner F, Verhoef G, Sonet A, Cuneo A, Goswami T, Ibrahim R, Cheson B. Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies. Poster Presentation: ASH 2013, New Orleans, LA.
 60. Lust J, Barranco C, Usmani S, Rhee R, **Hamadani M**, Dondero R, Browne L, Siegel D, Bensinger W. Phase 1b/2a open-label, dose-escalation study to evaluate the safety and tolerability of SNS01-T in patients with relapsed/refractory multiple myeloma, mantle cell lymphoma, or diffuse large B cell lymphoma. Poster Presentation: ASH 2013, New Orleans, LA.
 61. Efebera Y, Ranganathan P, Gibson L, Craig M, Fernandez-Cymering C, **Hamadani M**, Marcucci G, Devine SM, Fabbri M, Garzon R. Serum Mir-29a is up-regulated in acute graft versus host disease after allogeneic hematopoietic stem cell transplantation and activates dendritic cells. Poster Presentation: ASH 2013, New Orleans, LA.
 62. Kanate A, Rauenzahn S, Leadmon S, Truong Q, Cumpston A, Lonia L, Evans K, Zhang J, Wen S, Craig M, **Hamadani M**. Predictors and impact of 30-day readmissions on patient outcomes and healthcare costs after allogeneic transplantation. Poster Presentation: ASH 2013, New Orleans, LA.
 63. Forero A, **Hamadani M**, Kipps T, Fanale M, Cuneo A, Gladstone D, Andre M, Bellam N, Goswami T, Ibrahim R, Eck S, Elgeiyoushi N, Herbst R, Cheson B. Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab. Poster Presentation: SITC 2013, National Harbor, MD.
 64. Shah N, Rauenzahn S, Wen S, Craig M, Kanate A, **Hamadani M**, Cumpston A. Long term outcomes of autologous hematopoietic cell transplant following thiotepa-based high-dose therapy in patients with non-Hodgkin lymphoma. Poster Presentation: BMT Tandem Meetings 2014, Grapevine, TX.
 65. Kumar A, Reljic T, **Hamadani M**, Castrovinci P, Nishihori T, Ayala E, Savani B, Djulbegovic B, Kharfan-Dabaja M. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation intensification after rituximab-based front-line treatment of aggressive lymphomas: results of a systematic review and meta-analysis. Poster Presentation: EBMT 2014, Milan, IT.
 66. Dhakal B, Strouse C, Arce-Lara C, D'Souza A, Esselman J, Eastwood D, Pasquini C, Saber W, Drobyski W, Hari P, **Hamadani M**. Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL). Poster Presentation: ASCO 2014, Chicago, IL.
 67. **Hamadani M**, Hari P, Zhang Y, Carreras J, Maloney D, Smith S, Montoto S, Saber W. Early rituximab

- failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT). Poster Presentation: ASCO 2014, Chicago, IL.
68. Gonzalez R, Shillingburg A, Newton M, Wen S, Leadmon S, Kanate A, Craig M, **Hamadani M**, Cumpston C. Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell (HPC) mobilization. Poster Presentation: ASCO 2014, Chicago, IL.
69. Kumar S, Berdeja J, Niesvizky R, Lonial S, Laubach J, **Hamadani M**, Stewart K, Hari P, Roy V, Vescio R, Kaufman J, Berg D, Liao E, Hui A, Rajkumar S, Richardson P. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma: phase 2 study results. Oral Presentation: ASH 2014, San Francisco, CA.
70. Veltri L, Cumpston A, Shillingburg A, Lipinski C, Wen S, Leadmon S, Watkins K, Craig M, **Hamadani M**, Kanate A. Cost and efficacy of upfront plerixafor versus a “just-in-time” (JIT) approach in hematopoietic progenitor cell (HPC) mobilization. Poster Presentation: ASH 2014, San Francisco, CA.
71. Satwani P, Ahn K, Carreras J, Maloney D, Sureda A, Smith S, **Hamadani M**. Risk factors predicting outcomes of autologous hematopoietic cell transplantation (autoHCT) in children, Adolescents and young adults (CAYA) with relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (HL): A CIBMTR analysis. Oral Presentation: BMT Tandem Meetings 2015, San Diego, CA.
72. Bachanova V, Burns L, Ahn K, Carreras J, Maloney D, Sureda A, Smith S, **Hamadani M**. Positive pre-allogeneic hematopoietic cell transplantation (alloHCT) PET scan in patients with non-Hodgkin lymphoma (NHL) predicts higher risk of relapse but has no impact on survival. Oral Presentation: BMT Tandem Meetings 2015, San Diego, CA.
73. Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Maloney D, Smith S, Sureda A, Carreras J, **Hamadani M**. Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors. Oral Presentation: ASCO 2015, Chicago, IL.
74. Veltri L, Dhakal B, Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, Esselman J, Pasquini M, Fenske T, Hari P, **Hamadani M**, Kanate A. Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies. Poster Presentation: ASCO 2015, Chicago, IL.
75. Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Maloney D, Smith S, Sureda A, Carreras J, **Hamadani M**. Reduced intensity conditioning (RIC) allo transplantation is associated with superior long-term disease control in relapsed/refractory grade I/II (G-I/II) follicular lymphoma. Oral Presentation: 19th Congress of the EHA 2015, Milan, IT.
76. Sureda A, Zhang M, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, **Hamadani M**, Pasquini M. Allogeneic stem cell transplantation for relapsed/refractory (R/R) follicular lymphoma (FL). a joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Oral Presentation: ASH 2015, Orlando, FL.
77. Kharfan-Dabaja M, Reljic T, El-Asmar J, Nishihori T, Ayala A, **Hamadani M**, Ambuj K. Myeloablative or reduced intensity conditioning allogeneic hematopoietic cell transplantation for mantle cell lymphoma? a systematic review and meta-analysis. Poster Presentation: ASH 2015, Orlando, FL.
78. Dhakal B, Ramalingam S, Shuff J, Epperla N, Rein L, Banerjee A, Siker M, Hosking P, Hari P, D'Souza A, Atallah E, Ericksen B, Fenske T, **Hamadani M**. Local control of ocular adnexal lympho-proliferative disorders (OALD): Similar Outcomes in MALT and non-MALT histologies. Poster Presentation: ASH 2015, Orlando, FL.
79. El-Asmar J, Reljic T, Ayala A, Nishihori T, **Hamadani M**, Ambuj K, Kharfan-Dabaja M. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T-cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a meta-analysis. Poster Presentation: ASH 2015, Orlando, FL.
80. Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D, Maziarz R, Warlick E, Fernandez H, Alyea E, **Hamadani M**, Bashey A, Giralt S, Leifer E, Geller N, Le-Rademacher J, Mendizabal M, Horowitz M, Deeg J, Horwitz M. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Oral Presentation: ASH, 2015, Orlando, FL.
81. Mussetti A, Kanate A, Kharfan-Dabaja M, Ahn K, DiGilio A, Ciurea S, Armand P, Salit R, Fenske T, Smith S, Sureda A, Bolanos-Meade J, **Hamadani M**. Survival after T-cell replete haploidentical related

- donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoid malignancies. Oral Presentation: ASH 2015, Orlando, FL.
82. Chen Y, Le-Rademacher J, Kiefer D, **Hamadani M**, DiPersio J, Litzow M, Craig M, Horwitz M, Artz A, McClune B, Waller E, Fernandez H, Duong H, Kobusingye H, Proue M, Drexler R, Horowitz M, Miller J, Devine S. A Phase II study evaluating the safety and efficacy of subcutaneous plerixafor for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in recipients with hematological malignancies. Oral Presentation: ASH 2015, Orlando, FL.
83. Fenske T, Graff T, Ahn K, Digilio A, Smith S, Sureda A, **Hamadani M**. Reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) provides durable progression-free survival (PFS) in a subset of diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous (auto-) HCT. Oral Poster Presentation: ASH 2015, Orlando, FL.
84. **Hamadani M**, Pasquini MC, Visotcky A, Ahn KW, Horowitz M, Boyd J, Rizzo J, Saber W, Drobyski W, Arce-Lara C, D'Souza A, Fenske T, Cumpston A, Bunner P, Craig M, Hari P, Kanate A. Prospective, multicenter clinical trial of atorvastatin-based acute graft-versus-host-disease (aGVHD) prophylaxis in recipients of HLA-matched related donor (MRD) and matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (alloHCT). Oral Presentation: BMT Tandem Meetings 2016, Honolulu, HI.
85. Karmali R, Ghosh N, Rocha V, Ahn K, DiGilio A, Armand P, Salit R, Fenske T, Smith S, Sureda A, Johnston N, Bolanos-Meade J, **Hamadani M** Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphomas. Oral Presentation: BMT Tandem Meetings 2016, Honolulu, HI.
86. Shillingburg A, Craig M, Kanate A, **Hamadani M**, Cumpston A Treatment of severe mucositis pain with oral ketamine mouthwash. Biology of Blood and Marrow Transplantation. Poster Presentation: BMT Tandem Meetings 2016, Honolulu, HI.
87. Hari P, Kanate A, Pasquini M, Saber W, Drobyski W, Horowitz M, Rizzo J, Craig M, **Hamadani M**. Atorvastatin is effective for graft versus host disease prophylaxis – Results of a phase II prospective trial. Oral Presentation: EBMT 2016, Valencia, Spain.
88. Sureda A, Zhang M, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, **Hamadani M**, Pasquini M. Allogeneic stem cell transplantation for relapsed/refractory (R/R) follicular lymphoma (FL). A joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Oral Presentation: EBMT 2016, Valencia, Spain.
89. Mateos M, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson S, Stoppa A, Gimsing P, **Hamadani M**, Borsaru G, Berg D, Lin J, Velde H, Richardson P, Moreau P. “Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. Poster Presentation: ASCO 2016, Chicago, IL.
90. Chung Ki, **Hamadani M**, Kahl B, Heffner L, Caimi P, Feingold J, O'Connor O. A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL). Poster Presentation: ASCO 2016, Chicago, IL.
91. Guru Murthy G, Mehta P, Hari P, **Hamadani M**. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL). Poster Presentation: ASCO 2016, Chicago, IL.
92. Epperla N, **Hamadani M**, Ahn K, Oak E, Cashen A, Kanate A, Calzada O, Farmer Z, Tallarico M, Nabhan C, Costa L, Kenkre V, Ghosh N, Cohen J, Hari P, Fenske T. Allogeneic hematopoietic cell transplantation (AHCT) for hematological malignancies (HM) in United States: A comparison of hospitalization outcomes between young and elderly patients. Poster Presentation: ASCO 2016, Chicago, IL.
93. Kline J, Armand P, Kuruvilla J, Moskowitz C, **Hamadani M**, Ribrag V, Zinzani P, Chlosta S, Thompson S, Balakumaran A, Bartlett N: “KEYNOTE-013: An open-label, multicohort phase 1b trial of pembrolizumab for advanced hematologic malignancies.” *Journal for ImmunoTherapy of Cancer*. 2016;4:Suppl 1. [Poster Presentation]
94. Khalil M, Reljic T, El-Asmar, **Hamadani M**, Nishihori T, Ayala E, Kumar A, Kharfan-Dabaja M: “Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for myelofibrosis: A side-by-side systematic review/meta-analysis” *Blood* (ASH Annual Meeting Abstracts), 2016;128:3551. [Poster

- Presentation]
95. Costa L, Landau H, Chhabra S, Hari P, Salzman D, Saad A, Innis-Shelton R, **Hamadani M**, Tamari R, Godby K, Petrovic V, Orlando E, Williams L, Dixon P, Giralt S: "Carfilzomib plus high dose melphalan conditioning prior to autologous hematopoietic cell transplantation followed by carfilzomib maintenance in patients with relapsed multiple myeloma." *Blood (ASH Annual Meeting Abstracts)*, 2016;128:4630. [Poster Presentation]
 96. Wang M, Martin P, Phillips T, Goy A, Lossos I, Rule S, **Hamadani M**, Ghosh N, Reeder C, Barnett E, Bravo M, Schuster S: "Effectiveness of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib: The MCL-004 study." *Blood (ASH Annual Meeting Abstracts)*, 2016;128:1786. [Poster Presentation]
 97. Bashey A, Zhang M, McCurdy S, Ciurea S, Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, **Hamadani M**, Al-Malki M, Munshi P, Nakamura R, O'Donnell P, Perales M, Raj K, Rocha V, Romee R, Rowley S, Salit R, Solh M, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M: "Comparison of peripheral blood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-haploidentical donor transplantation using post-transplant cyclophosphamide." *Blood (ASH Annual Meeting Abstracts)*, 2016;128:683. [Oral Presentation]
 98. Maddocks K, Epperla E, Chavez J, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain N, Hernandez-Ilizaliturri F, Al-Mansour Z, Barta S, Chhabra S, Lansigan F, Mehta A, Jaglal M, Evans E, Peker D, Forero-Torres A, Flowers C, Fenske T, Cohen J, **Hamadani M**, Costa L: "Diffuse large B-cell Lymphoma with primary treatment failure: identification of ultra-high risk patients and benchmarking for experimental therapies." *Blood (ASH Annual Meeting Abstracts)*, 2016;128:103. [Oral Presentation]
 99. Costa L, Reddy N, Maddocks K, Epperla E, Chavez J, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain N, Hernandez-Ilizaliturri F, Al-Mansour Z, Barta S, Chhabra S, Lansigan F, Mehta A, Jaglal M, Evans E, Peker D, Forero-Torres A, Flowers C, Fenske T, Cohen J, **Hamadani M**: "Primary failure diffuse large B-cell lymphoma: early autologous or donor hematopoietic cell transplantation not effective in patients with ultra-high risk features." *Blood (ASH Annual Meeting Abstracts)*, 2016;128:103. [Oral Presentation]
 100. Casulo C, Friedberg JW, Ahn K, DiGilio A, Sureda A, Fenske T, Smith S, **Hamadani M**: "Autologous transplantation (autoHCT) is associated with improved overall survival (OS) in follicular lymphoma (FL) patients (Pts) experiencing early therapy failure after frontline chemo-immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis." *Biology of Blood and Marrow Transplantation*. March 2017;23(3):S46-47. [Oral Presentation]
 101. Epperla N, Kodali D, Kleman A, Hari P, Pasquini M, D'Souza A, Saber W, Shah N, Fenske T, Craig M, Kanate A, **Hamadani M**: "Post-relapse survival in lymphoma patients (Pts) after experiencing therapy failure following an allogeneic hematopoietic cell transplantation (alloHCT)." *Biology of Blood and Marrow Transplantation*. March 2017;23(3):S48. [Oral Presentation]
 102. Epperla N, Ahn K, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine S, Jaglowski S, Kharfan-Dabaja M, Kennedy V, Rezvani A, Smith S, Sureda A, Fenske T, **Hamadani M**: "Rituximab (R) versus non-rituximab (NR) containing reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in B-cell non-Hodgkin lymphomas (B-NHL): A CIBMTR Analysis." *Biology of Blood and Marrow Transplantation*. March 2017;23(3):S47-S48. [Oral Presentation]
 103. Kanate A, Olteanu H, Ahn K, DiGilio A, Sureda A, Fenske T, Smith S, **Hamadani M**: "Allogeneic hematopoietic cell transplantation (alloHCT) for extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL): A CIBMTR analysis." *Biology of Blood and Marrow Transplantation*. March 2017;23(3):S49-S50. [Oral Presentation]
 104. Godfrey J, Smith S, Ahn K, DiGilio A, Fenske T, Sureda A, **Hamadani M**: "Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis." *J Clin Oncol*. 2017;35:(suppl; abstr 7508). [Oral Presentation]
 105. Horwitz SM, Fanale M, Spira A, Havenith K, He S, Feingold J, **Hamadani M**: "Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory Hodgkin/non-Hodgkin lymphoma." *Hematol Oncol*. 2017 35: Supplement S2. 14-ICML, 14th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano (Switzerland). [Poster Presentation]
 106. Kahl B, **Hamadani M**, Caimi P, Reid E, Havenith K, He S, Feingold J, O'Connor O: "First clinical results

- of ADCT-402, a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma.” 2017 35: Supplement S2. 14-ICML, 14th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano (Switzerland). [Oral Presentation]
107. Horwitz S, **Hamadani M**, Fanale M, Feingold J, Spira A, Fields P, Menne T, Karnad A, Moskowitz A, Hildyard C, He S, Boni J, Collins G: “Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma.” *Blood (ASH Annual Meeting Abstracts)*, 2017;130:1510. [Poster Presentation]
 108. Pawarode A, D'Souza A, Pasquini M, Johnson B, Braun T, Dhakal B, **Hamadani M**, Magenau J, Shah N, Riwes M, Parkin B, Reddy P, Hari P: “Phase 2 study of pembrolizumab during lymphodepleted state after autologous hematopoietic cell transplantation in multiple myeloma patients.” *Blood (ASH Annual Meeting Abstracts)*, 2017;130:339. [Oral Presentation]
 109. Kahl B, **Hamadani M**, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshta K, Radford J, Solh M, Chung K, Heffner L, He S, Boni J, O'Connor O: “Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma.” *Blood (ASH Annual Meeting Abstracts)*, 2017;130:187. [Oral Presentation]
 110. Chhabra S, Hari P, Visotcky A, Shah N, Rizzo J, Saber W, D'Souza A, Dhakal B, Anshu A, Thompson R, Fenske T, Shaw B, Drobyski W, Pasquini **Hamadani M**: “Ixazomib for chronic graft-versus-host-disease (cGVHD) prophylaxis in patients undergoing allogeneic transplantation (alloHCT): Preliminary results of a phase I/II study.” *Blood (ASH Annual Meeting Abstracts)*, 2017;130:1974. [Poster Presentation]
 111. Badar T, **Hamadani M**, Bachanova V, Maddocks K, Umyarova E, Chavez J, Epperla N, Chhabra S, Xavier A, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri F, Flowers C, Evens A, Zhou Z, Lansigan F, Barta S, Cohen J, Fenske T, Costa L: “Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.” *Blood (ASH Annual Meeting Abstracts)*, 2017;130:4141. [Poster Presentation]
 112. Shah N, Ahn K, Litovich C, Sureda A, Smith S, Fenske T, **Hamadani M**. Outcomes of patients 65 years and older with non-Hodgkin lymphoma receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age: A CIBMTR analysis. *Biology of Blood and Marrow Transplantation*. March 2018;24(3):S77-S78. [Oral Presentation]
 113. Levis M, **Hamadani M**, Logan B, Rosales M, Perl A, Devine S, Bahceci E, Chen YB. A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. *J Clin Oncol*. 2018;36:(suppl; abstr TPS7075). [Poster Presentation]
 114. **Hamadani M**, Ahn KW, Litovich C, Herve F, Smith S, Fenske T, Boumendil A, Dietrich S, Robinson S, Montoto S, Dreger P, Sureda A. Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis. *J Clin Oncol*. 2018;36:(suppl; abstr 7056). [Poster Presentation]
 115. **Hamadani M**, Collins G, Samaniego F, Spira A, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, Horwitz S. Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. *Blood (ASH Annual Meeting Abstracts)*, 2018;132:928. [Oral Presentation]
 116. Epperla N, Ahn K, Litovich C, Kharfan-Dabaja K, Sonali S, Sureda A, Fenske T, **Hamadani M**. Impact of allogeneic hematopoietic cell transplantation (allo-HCT) on the outcomes of angioimmunoblastic T-cell lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. *Blood (ASH Annual Meeting Abstracts)*, 2018;132:969. [Oral Presentation]
 117. Collins G, Horwitz S, Davies A, Karnad A, Samaniego F, Spira A, Fields P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, **Hamadani M**. Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a phase 1 study of relapsed/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma. *Blood (ASH Annual Meeting Abstracts)*, 2018;132:1658. [Poster Presentation]
 118. Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D'Souza A, Pasquini M, Hari P, **Hamadani M**. Incidence and predictors of 30-day readmissions following autologous hematopoietic cell transplantation (auto-HCT) in the U.S. *Blood (ASH Annual Meeting Abstracts)*, 2018;132:3544. [Poster Presentation]
 119. Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D'Souza A, Pasquini M, Hari

- P, **Hamadani M.** Association between transplant volumes and 30-day readmission following allogeneic hematopoietic cell transplantation (allo-HCT) in the U.S. *Blood (ASH Annual Meeting Abstracts)*, 2018;132:617. [Poster Presentation]
120. Kanakry J, Ahmed S, Ahn K, Litovich C, Kharfan-Dabaja M, Fenske T, Sureda A, **Hamadani M.** Post-transplant cyclophosphamide (PTCy)-based haploidentical (Haplo) donor vs. calcineurin-inhibitor (CNI)-based matched related donor (MRD) reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT) for classical Hodgkin lymphoma (cHL). *Biology of Blood and Marrow Transplantation*. March 2019;25(3):S406–S407. [Poster Presentation]
121. Pidala J, **Hamadani M.**, Dawson P, Alousi A, Jagasia M, Efebera Y, Chhabra S, Pusic I, Holtan S, Ferrara J, Levine J, Anasetti C, Pritchard T, Martens M, Horowitz M, MacMillan M. Sirolimus vs. prednisone as initial systemic therapy for Minnesota standard risk (MN-SR), Ann Arbor 1/2 acute graft-vs-host disease (GVHD): primary results of the multi-center randomized phase II BMT CTN 1501 trial. *Biology of Blood and Marrow Transplantation*. March 2019;25(3):S50–S51. [Oral Presentation]
122. Chhabra S, Hari P, Visotcky A, Zhu F, Cantrall K, Abedin S, Dhakal B, D’Souza A, Drobyski W, Fenske T, Jerkins J, Rizzo JD, Runaas, Saber W, Shah N, Shaw B, Pasquini M, **Hamadani M.** Phase I/2 study of ixazomib for chronic graft-versus-host disease (cGVHD) prophylaxis after allogeneic transplantation (alloHCT). *Biology of Blood and Marrow Transplantation*. March 2019;25(3):S224–S225. [Poster Presentation]
123. Ghosh N., Ahmed S., Litovich C., Ahn K., Khanal M., Kharfan-Dabaja M., Sureda A., Fenske T., **Hamadani M.**: “Comparison of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in non-Hodgkin lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) analysis.” *Blood (ASH Annual Meeting Abstracts)*, 2019;134:319. [Oral Presentation]
124. Ahmed S., Ghosh N., Litovich C., Ahn K., Khanal M., Kharfan-Dabaja M., Sureda A., Fenske T., **Hamadani M.**: “Comparison of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in classical Hodgkin lymphoma-a Center for International Blood & Marrow Transplant Research (CIBMTR) analysis.” *Blood (ASH Annual Meeting Abstracts)*, 2019;134:3318. [Poster Presentation]
125. Jagadeesh D., Majhail N., Yizeng H., Litovich C., Ahn K., Kharfan-Dabaja M., Sureda A., Fenske T., **Hamadani M.**: “Does addition of rituximab (R) to BEAM conditioning improve outcomes of patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT)?” *Blood (ASH Annual Meeting Abstracts)*, 2019;134:785. [Oral Presentation]